



## Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

PDL Updated January 21, 2022

Updates include November 2021 P&T Changes and new updates  
since the January 3<sup>rd</sup> posting

Highlighted in **Red Font**

For the most up to date list of covered drugs consult the Drug Lookup on the Nebraska Medicaid Website at <https://druglookup.fhsc.com/druglookupweb/?client=nestate>

- **Opioids**- The maximum opioid dose covered will decrease from 120 Morphine Milligram Equivalents (MME) per day to 90 Morphine Milligram Equivalents (MME) per day. (beginning December 1, 2020)

### Non-Preferred Drug Coverage

Class and drug-specific therapeutic trial and failure requirements are found within this document.

Examples of non-preferred exception criteria include:

- Adverse reaction to preferred drugs
- Allergy to preferred drugs
- Contraindication to preferred drugs
- Documentation of inability to swallow solid dosage forms

Specific Class Prior Authorization forms can be found within the PDL class listings and at:

<https://nebraska.fhsc.com/priorauth/paforms.asp>

- [Asthma Immunomodulator PA Form](#)
- [Buprenorphine Products PA Form](#)
- [Buprenorphine Products Informed Consent](#)
- [Growth Hormone PA Form](#)
- [HAE Treatments PA Form](#)
- [Hepatitis C PA Form](#)

For all other class medically-necessary coverage, quantity, and high dose requests use the following:

- [Documentation of Medical Necessity PA Form](#)

For a complete list of Claims Limitations visit:

<https://nebraska.fhsc.com/Downloads/neclaimlimitations.pdf>

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ACNE AGENTS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
benzoyl peroxide (BPO) <b>WASH, LOTION</b> clindamycin/BPO (generic Duac) clindamycin phosphate <b>PLEDGET</b> clindamycin phosphate <b>SOLUTION</b> DIFFERIN <b>LOTION, CREAM, Rx-GEL</b> (adapalene) DIFFERIN <b>GEL</b> (adapalene) OTC erythromycin <b>GEL</b> erythromycin <b>SOLUTION</b> erythromycin-BPO (generic for Benzamycin) RETIN-A (tretinoin) <sup>AL</sup> <b>CREAM, GEL</b>	adapalene (generic differin) adapalene/BPO (generic Epiduo) adapalene/BPO (generic Epiduo Forte) <sup>NR</sup> <i>AKLIEF (trifarotene)<sup>AL</sup></i> ALTRENO (tretinoin) <sup>AL</sup> <i>AMZEEQ (minocycline)</i> <i>ARAZLO (tazarotene)<sup>AL</sup></i> ATRALIN (tretinoin) AVAR (sulfacetamide sodium/sulfur) AVITA (tretinoin) AZELEX (azelaic acid) BENZACLIN <b>PUMP</b> (clindamycin/BPO) BENZEFOAM (benzoyl peroxide) <sup>NR</sup> benzoyl peroxide <b>CLEANSER, CLEANSING BAR</b> OTC benzoyl peroxide <b>FOAM</b> (generic Benzepro) benzoyl peroxide <b>GEL</b> OTC benzoyl peroxide <b>GEL</b> Rx <i>benzoyl peroxide TOWELETTE</i> OTC clindamycin <b>FOAM, LOTION</b> clindamycin <b>GEL</b> clindamycin phosphate (generic for Clindagel) <sup>NR</sup> <b>GEL</b> clindamycin/BPO (generic Acanya, Benzaclin) <b>GEL</b> clindamycin/tretinoin (generic Veltin, Ziana) dapsone (generic Aczone) EPIDUO FORTE <b>GEL PUMP</b> (adapalene/BPO) erythromycin <b>GEL, PLEDGET</b> erythromycin-BPO (generic for Benzamycin) EVOCLIN (clindamycin) FABIOR (tazarotene foam) NEUAC (clindamycin/BPO) ONEXTON (clindamycin/BPO) OVACE PLUS (sulfacetamide sodium) PLIXDA (adapalene) SWAB <i>RETIN-A GEL, CREAM<sup>AL</sup> (tretinoin)</i> sulfacetamide sulfacetamide/sulfur SUMADAN (sulfacetamide/sulfur) tazarotene <b>CREAM</b> (generic Tazorac) <i>tazarotene FOAM (generic Fabior)<sup>NR</sup></i> TRETIN-X (tretinoin) tretinoin CREAM, GELAL (generic Avita, Retin-A) tretinoin microspheres (generic for Retin-A Micro) <sup>AL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed THREE preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ALZHEIMER'S AGENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CHOLINESTERASE INHIBITORS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 120-day trial of ONE preferred agent within this drug class within the last 6 months</li> <li><b>OR</b></li> <li>Current, stabilized therapy of the non-preferred agent within the previous 45 days</li> </ul>
donepezil (generic for Aricept) donepezil ODT (generic for Aricept ODT) EXELON Transdermal (rivastigmine)	donepezil 23 (generic for Aricept 23) galantamine (generic for Razadyne) <b>SOLUTION, TABLET</b> galantamine ER (generic for Razadyne ER) rivastigmine (generic for Exelon)	
<b>NMDA RECEPTOR ANTAGONIST</b>		Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Donepezil 23:</b> Requires donepezil 10mg/day for at least 3 months AND clinical reason as to why 5mg or 10mg tablets can't be used (to deliver 20mg or 25mg)</li> </ul>
memantine (generic for Namenda)	memantine ER (generic for Namenda XR) memantine <b>SOLUTION</b> (generic for Namenda) NAMENDA (memantine) NAMZARIC (memantine/donepezil)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANALGESICS, OPIOID LONG-ACTING

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
BUTRANS (buprenorphine) <sup>QL</sup> <b>PATCH</b> fentanyl 25, 50, 75, 100 mcg <b>PATCH</b> <sup>QL</sup> morphine ER <b>TABLET</b> (generic MS Contin, Oramorph SR) OXYCONTIN <sup>CL</sup> (oxycodone ER) tramadol ER (generic Ultram ER) <sup>CL</sup>	ARYMO ER (morphine sulfate) <sup>QL</sup> BELBUCA (buprenorphine) <sup>QL</sup> <b>BUCCAL</b> buprenorphine <b>BUCCAL</b> (generic for Belbuca) <sup>AL,NR,QL</sup> buprenorphine <b>PATCH</b> (generic Butrans) <sup>QL</sup> <i>EMBEDA (morphine sulfate/naltrexone)</i> DURAGESIC MATRIX (fentanyl) <sup>QL</sup> fentanyl 37.5, 62.5, 87.5 mcg <b>PATCH</b> <sup>QL</sup> <i>hydrocodone ER (generic for Hysingla ER)</i> <sup>NR, QL</sup> hydrocodone bitartrate ER (generic for Zohydro ER) hydromorphone ER (generic for Exalgo) <sup>CL</sup> HYSINGLA ER (hydrocodone ER) KADIAN (morphine ER) methadone <b>TABLET, ORAL SYR</b> <sup>NR,CL</sup> MORPHABOND ER (morphine sulfate) morphine ER (generic for Avinza, Kadian) <b>CAPSULE</b> NUCYNTA ER (tapentadol) <sup>CL</sup> oxycodone ER (generic Oxycontin) oxymorphone ER (generic Opana ER) tramadol ER (generic Conzip) <sup>CL</sup>	The Center for Disease Control (CDC) does not recommend long acting opioids when beginning opioid treatment. <ul style="list-style-type: none"> <li>• Preferred agents require previous use of a long acting opioid or documentation of a trial on a short acting agent within 90 days</li> <li>• Non-preferred agents will be approved with failure on, or intolerance to TWO preferred agents within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>• <b>Methadone:</b> Will only be approved for use in pain control or end of life care. Trial of preferred agent not required for end of life care</li> <li>• <b>Oxycontin®:</b> Pain contract required for maximum quantity authorization</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANALGESICS, OPIOID SHORT-ACTING<sup>QL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
	<b>ORAL</b>	
acetaminophen/codeine <b>ELIXIR, TABLET</b> codeine <b>TABLET</b> hydrocodone/APAP <b>SOLUTION, TABLET</b> hydrocodone/ibuprofen hydromorphone <b>TABLET</b> morphine <b>CONC SOLUTION, SOLUTION, TABLET</b> oxycodone <b>TABLET, SOLUTION</b> oxycodone/APAP Tramadol 50 <b>TABLET</b> <sup>AL</sup> (generic Ultram) tramadol/APAP (generic Ultracet)	APADAZ (benzhydrocodone/APAP) <sup>CL</sup> benzhydrocodone/APAP (generic Apadaz) <sup>CL</sup> butalbital/caffeine/APAP/codeine butalbital compound w/codeine (butalbital/ASA/caffeine/codeine) carisoprodol compound-codeine (carisoprodol/ASA/codeine) dihydrocodeine/APAP/caffeine dihydrocodeine/aspirin/caffeine FIORINAL/CODEINE (butalbital/ASA/codeine/caffeine) hydromorphone <b>LIQUID, SUPPOSITORY</b> (generic Dilaudid) IBUDONE (hydrocodone/ibuprofen) levorphanol meperidine (generic Demerol) morphine <b>SUPPOSITORIES</b> NALOCET (oxycodone/APAP) NUCYNTA (tapentadol) <sup>CL</sup> OXAYDO (oxycodone) <sup>CL</sup> oxycodone <b>CAPSULE</b> oxycodone/APAP <b>SOLUTION</b> oxycodone/APAP <b>TABLET</b> (generic Prolate) oxycodone/aspirin oxycodone <b>CONCENTRATE</b> oxycodone/ibuprofen oxymorphone IR (generic Opana) pentazocine/naloxone PROLATE <b>SUSP</b> (oxycodone/acetaminophen) <sup>NR</sup> ROXICODONE <b>TABLET</b> (oxycodone) tramadol 100mg <b>TABLET</b> (generic Ultram) <sup>AL</sup> ROXYBOND (oxycodone) ZAMICET (hydrocodone/APAP)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed THREE preferred agents within this drug class within the last 12 months</li> <li>Note: for short acting opiate tablets and capsules there is a maximum quantity limit of #150 per 30 days.</li> <li>Beginning Oct. 11, 2018: Opiate limits for opiate naïve patients will consist of               <ul style="list-style-type: none"> <li>-prescriptions limited to a 7 day supply, AND</li> <li>-initial opiate prescription fill limited to maximum of 50 Morphine Milligram Equivalents (MME) per day</li> </ul>               These limits may only be exceeded with patient specific documentation of medical necessity, with examples such as, cancer diagnosis, end-of-life care, palliative care, Sickle Cell Anemia, or prescriber attestation that patient is not recently opiate naïve             </li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Apadaz:</b> Approval for 14 days or less</li> <li><b>Nucynta®:</b> Approved only for diagnosis of acute pain, for 30 days or less</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANALGESICS, OPIOID SHORT-ACTING<sup>QL</sup> (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>NASAL</b>		
	butorphanol <b>SPRAY</b> <sup>QL</sup> LAZANDA (fentanyl citrate)	Drug-specific criteria: <ul style="list-style-type: none"> <li>• <b>Abstral®/Actiq®/Fentora®/Onsolis (fentanyl)</b>: Approved only for diagnosis of cancer AND current use of long-acting opiate</li> </ul>
<b>BUCCAL/TRANSMUCOSAL</b> <sup>CL</sup>		
	ABSTRAL (fentanyl) <sup>CL</sup> fentanyl <b>TRANSMUCOSAL</b> (generic Actiq) <sup>CL</sup> FENTORA (fentanyl) <sup>CL</sup>	

## ANDROGENIC AGENTS (Topical)<sup>CL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<i>ANDROGEL (testosterone) <b>PUMP</b></i> <sup>CL</sup>	ANDRODERM (testosterone) <sup>CL</sup> NATESTO (testosterone) <sup>CL</sup> testosterone PACKET (generic Androgel) <sup>CL</sup> <i>testosterone <b>PUMP</b></i> (generic Androgel) <sup>CL</sup> <i>testosterone <b>GEL, PACKET, PUMP</b></i> (generic Vogelxo) testosterone (generic Axiron) testosterone (generic Fortesta) testosterone (generic Testim)	<ul style="list-style-type: none"> <li>• Preferred agents approved for diagnosis of Primary hypogonadism (congenital or acquired) or Hypogonadotropic hypogonadism. Off label use for the following will be considered with documentation of necessity: female to male transsexual – gender dysphoria, weight gain, male osteoporosis, delayed puberty in males, corticosteroid-induced hypogonadism and osteoporosis, inoperable carcinoma of the breast, postpartum breast pain and engorgement, and menopause</li> <li>• In addition, non-preferred agents will be approved for patients who have failed ONE preferred agent within this drug class within the last 6 months</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>• <b>Androderm®/Androgel®</b>: Approved for Males only</li> <li>• <b>Natesto®</b>: Approved for Males only with diagnosis of: Primary hypogonadism (congenital or acquired) OR Hypogonadotropic hypogonadism (congenital or acquired)</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANGIOTENSIN MODULATORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ACE INHIBITORS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ONE preferred agent within this drug class within the last 12 months</li> <li>Non-preferred combination products may be covered as individual prescriptions without prior authorization</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Epaned® and Qbrelis® Oral Solution:</b> Clinical reason why oral tablet is not appropriate</li> </ul>
benazepril (generic Lotensin) enalapril (generic Vasotec) <i>fosinopril (generic Monopril)</i> lisinopril (generic Prinivil, Zestril) quinapril (generic Accupril) ramipril (generic Altace)	captopril (generic Capoten) EPANED (enalapril) <sup>CL</sup> <b>ORAL SOLUTION</b> enalapril (generic for Epaned) <sup>CL</sup> <b>ORAL SOLUTION</b> moexepiril (generic Univasc) perindopril (generic Aceon) QBRELIS (lisinopril) <sup>CL</sup> <b>ORAL SOLUTION</b> trandolapril (generic Mavik)	
<b>ACE INHIBITOR/DIURETIC COMBINATIONS</b>		
benazepril/HCTZ (generic Lotensin HCT) enalapril/HCTZ (generic Vaseretic) fosinopril/HCTZ (generic Monopril HCT) lisinopril/HCTZ (generic Prinzide, Zestoretic) quinapril/HCTZ (generic Accuretic)	captopril/HCTZ (generic Capozide) moexipril/HCTZ (generic Uniretic)	
<b>ANGIOTENSIN RECEPTOR BLOCKERS</b>		
irbesartan (generic Avapro) losartan (generic Cozaar) olmesartan (generic Benicar) valsartan (generic Diovan)	candesartan (generic Atacand) EDARBI (azilsartan) eprosartan (generic Teveten) telmisartan (generic Micardis)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANGIOTENSIN MODULATORS (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ANGIOTENSIN RECEPTOR BLOCKER/DIURETIC COMBINATIONS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed TWO preferred agents within this drug class within the last 12 months</li> <li>Non-preferred combination products may be covered as individual prescriptions without prior authorization</li> </ul>
irbesartan/HCTZ (generic Avalide) losartan/HCTZ (generic Hyzaar) olmesartan/HCTZ (generic Benicar-HCT) valsartan/HCTZ (generic Diovan-HCT)	candesartan/HCTZ (generic Atacand-HCT) EDARBYCLOR (azilsartan/chlorthalidone) telmisartan/HCTZ (generic Micardis-HCT)	
<b>ANGIOTENSIN MODULATOR/ CALCIUM CHANNEL BLOCKER COMBINATIONS</b>		<ul style="list-style-type: none"> <li><b>Angiotensin Modulator/Calcium Channel Blocker Combinations:</b> Combination agents may be approved if there has been a trial and failure of preferred agent</li> </ul>
amlodipine/benazepril (generic Lotrel) amlodipine/olmesartan (generic Azor) amlodipine/valsartan (generic Exforge)	amlodipine/olmesartan/HCTZ (generic Tribenzor) amlodipine/telmisartan (generic Twynsta) <i>amlodipine/valsartan/HCTZ (generic Exforge HCT)</i> PRESTALIA (perindopril/amlodipine) trandolapril/verapamil (generic Tarka)	
<b>DIRECT RENIN INHIBITORS</b>		<ul style="list-style-type: none"> <li><b>Direct Renin Inhibitors/Direct Renin Inhibitor Combinations:</b> May be approved with history of TWO preferred ACE Inhibitors or Angiotensin Receptor Blockers within the last 12 months</li> </ul>
	aliskiren (generic Tekturna) <sup>QL</sup>	
<b>DIRECT RENIN INHIBITOR COMBINATIONS</b>		Drug Specific Criteria <ul style="list-style-type: none"> <li><b>Entresto:</b> May be approved with a diagnosis of heart failure AND ≥ 18 years old</li> </ul>
	TEKTURNA/HCT (aliskiren/HCTZ)	
<b>NEPRILYSIN INHIBITOR COMBINATION</b>		
ENTRESTO (sacubitril/valsartan) <sup>AL,QL</sup>		
<b>ANGIOTENSIN RECEPTOR BLOCKER/BETA-BLOCKER COMBINATIONS</b>		
	BYVALSON (nevigolol/valsartan)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTHELMINTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
albendazole (generic for Albenza) BILTRICIDE (praziquantel) ivermectin (generic for Stromectol)	ALBENZA (albendazole) EMVERM (mebendazole) <sup>CL</sup> praziquantel (generic for Biltricide) STROMECTOL (ivermectin)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class within the last 6 months</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Emverm:</b> Approval will be considered for indications not covered by preferred agents</li> </ul>

## ANTI-ALLERGENS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
	ORALAIR (sweet vernal/orchard/rye/timothy/kentucky blue grass mixed pollen allergen extract) PALFORZIA <sup>AL,CL</sup> (peanut allergen powder-dnfp)	<p>Drug-specific criteria:</p> <p><b>ORALAIR</b></p> <ul style="list-style-type: none"> <li>Confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens.</li> <li>For use in patients 10 through 65 years of age.</li> </ul> <p><b>PALFORZIA</b></p> <ul style="list-style-type: none"> <li>Confirmed diagnosis of peanut allergy by allergist</li> <li>For use in patients ages 4 to 17; it may be continued in patients 18 years and older with documentation of previous use within the past 90 days</li> <li>Initial dose and increase titration doses should be given in a healthcare setting</li> <li>Should not be used in patients with uncontrolled asthma or concurrently on a NSAID</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIBIOTICS, GASTROINTESTINAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
FIRVANQ (vancomycin) <b>SOLUTION</b> metronidazole <b>TABLET</b> neomycin tinidazole (generic Tindamax) <sup>CL</sup>	DIFICID (fidaxomicin) <sup>CL</sup> <b>TABLET, SUSP<sup>NR</sup></b> FLAGYL ER (metronidazole) <sup>CL</sup> Metronidazole <sup>CL</sup> <b>CAPSULE</b> <i>nitazoxanide (generic Alinia)</i> <b>TABLET<sup>AL, CL, QL</sup></b> paromomycin SOLOSEC (secnidazole) vancomycin <b>CAPSULE</b> (generic Vancocin) <sup>CL</sup> XIFAXAN (rifaximin) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Note: Although azithromycin, ciprofloxacin, and trimethoprim/ sulfmethoxazole are not included in this review, they are available without prior authorization</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Alinia<sup>®</sup></b>: Trial and failure with metronidazole is required for a diagnosis of giardiasis</li> <li><b>Dificid<sup>®</sup></b>: Trial and failure with oral vancomycin is required for a diagnosis of C. difficile diarrhea (pseudomembranous colitis)</li> <li><b>Flagyl ER<sup>®</sup></b>: Trial and failure with metronidazole is required</li> <li><b>Flagyl<sup>®</sup>/Metronidazole 375mg capsules and Flagyl ER<sup>®</sup>/ Metronidazole 750mg ER tabs</b>: Clinical reason why the generic regular-release cannot be used</li> <li><b>tinidazole</b>:                              Approvable diagnoses include:                              Giardia                              Amebiasis intestinal or liver abscess                              Bacterial vaginosis or trichomoniasis</li> <li><b>vancomycin capsules</b>: Requires patient specific documentation of why the Firvanq/vancomycin solution is not appropriate for patient</li> <li><b>Xifaxan<sup>®</sup></b>: Approvable diagnoses include:                              Travelers's diarrhea resistant to quinolones                              Hepatic encephalopathy with treatment failure of lactulose or neomycin                              Diarrhea-Predominant IBS (IBS-D) 550mg strength only with treatment failure of Lomotil<sup>®</sup> AND Imodium<sup>®</sup></li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIBIOTICS, INHALED

Preferred Agents <sup>CL</sup>	Non-Preferred Agents	Prior Authorization/Class Criteria
BETHKIS (tobramycin) <sup>CL</sup> KITABIS PAK (tobramycin) <sup>CL</sup> TOBI-PODHALER (tobramycin) <sup>CL,QL</sup>	ARIKAYCE (amikacin liposomal inh) <sup>CL</sup> <b>SUSPENSION</b> CAYSTON (aztreonam lysine) <sup>QL,CL</sup> <i>tobramycin (generic for Bethkis)</i> tobramycin (generic Tobi) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Diagnosis of Cystic Fibrosis is required for all agents ICD10 Group = E84, ICD9 = 277.00, 277.01, 277.02, 277.03, 277.09</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Arikayce:</b> Requires diagnosis of refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy</li> <li><b>Cayston®:</b> Trial of tobramycin via nebulizer and demonstration of TOBI® compliance required</li> <li><b>Tobi Podhaler®:</b> Requires trial of tobramycin via nebulizer or documentation why nebulized tobramycin cannot be used</li> </ul>

## ANTIBIOTICS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
bacitracin <b>OINTMENT</b> bacitracin/polymyxin (generic Polysporin) mupirocin <b>OINTMENT</b> (generic Bactroban) neomycin/polymyxin/bacitracin (generic Neosporin, Triple AB) neomycin/polymyxin/pramoxine neomycin/polymyxin/bacitracin/pramoxine	CENTANY (mupirocin) gentamicin <b>OINTMENT, CREAM</b> mupirocin <b>CREAM</b> (generic Bactroban) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ALL preferred agents within this drug class within the last 12 months</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Mupirocin® Cream:</b> Clinical reason the ointment cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIBIOTICS, VAGINAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
CLEOCIN <b>OVULES</b> (clindamycin) clindamycin <b>CREAM</b> (generic Cleocin) CLINDESSE (clindamycin) NUVESSA (metronidazole) VANDAZOLE (metronidazole)	CLEOCIN <b>CREAM</b> (clindamycin) METROGEL (metronidazole) <i>metronidazole, vaginal</i>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a therapeutic trial (duration = 3 days) with ONE preferred agent within this drug class within the last 6 months</li> </ul>

## ANTICOAGULANTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ELIQUIS (apixaban) enoxaparin (generic Lovenox) PRADAXA (dabigatran) warfarin (generic Coumadin) XARELTO (rivaroxaban) 10 mg, 15 mg, 20 mg XARELTO (rivaroxaban) 2.5 mg <sup>CL,QL</sup> XARELTO DOSE PACK (rivaroxaban)	BEVYXXA (betrixaban) <sup>QL</sup> fondaparinux (generic Arixtra) FRAGMIN (dalteparin) SAVAYSA (edoxaban) <sup>QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ONE preferred agent within this drug class within the last 12 months</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Coumadin®</b>: Clinical reason generic warfarin cannot be used</li> <li><b>Savaysa®</b>: Approved diagnoses include:              Stroke and systemic embolism (SE) risk reduction in nonvalvular atrial fibrillation (NVAf) OR              Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of parenteral anticoagulant therapy</li> <li><b>Xarelto 2.5mg</b>: Use limited to reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in patients with chronic coronary artery disease or peripheral artery disease</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANTIEMETICS/ANTIVERTIGO AGENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CANNABINOIDS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ONE preferred agent within this drug class within the same group</li> </ul>
dronabinol (generic Marinol) <sup>AL</sup>	CESAMET (nabilone)	
<b>5HT3 RECEPTOR BLOCKERS</b>		<p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Akynzeo®/Varubi®:</b> Approved for Moderately/Highly emetogenic chemotherapy with dexamethasone and a 5-HT3 antagonist</li> <li><b>Regimens include:</b> AC combination (Doxorubicin or Epirubicin with Cyclophosphamide), Aldesleukin, Amifostine, Arsenic trioxide, Azacitidine, Bendamustine, Busulfan, Carmustine, Carbplatin, Cisplatin, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Epirubicin, Etoposide, Hexamethylmelamine, Idarubicin, Ifosfamide, Imatinib, Interferon α, Irinotecan, Mechlorethamine, Melphalan, Methotrexate, Oxaliplatin, Procarbazine, Streptozotocin, Temozolomide</li> <li><b>Diclegis®/Bonjesta:</b> Approved only for treatment of nausea and vomiting of pregnancy</li> <li><b>Metozolv ODT®:</b> Documentation of inability to swallow or Clinical reason oral liquid cannot be used</li> <li><b>Sancuso®/Zuplenz®:</b> Documentation of oral dosage form intolerance</li> </ul>
ondansetron (generic Zofran/Zofran ODT) <sup>QL</sup>	ANZEMET (dolasetron) granisetron (generic Kytril) SANCUSO (granisetron) <sup>CL</sup> ZUPLENZ (ondansetron)	
<b>NK-1 RECEPTOR ANTAGONIST</b>		
EMEND (aprepitant) <b>CAPSULE, CAPSULE PACK</b> <sup>QL</sup>	aprepitant (generic Emend) <sup>QL,CL</sup> AKYNZEO (netupitant/palonosetron) <sup>CL</sup> VARUBI (rolapitant) <b>TABLET</b> <sup>CL</sup>	
<b>TRADITIONAL ANTIEMETICS</b>		
DICLEGIS (doxylamine/pyridoxine) <sup>CL,QL</sup>	BONJESTA	
dimenhydrinate (generic Dramamine) OTC	(doxylamine/pyridoxine) <sup>CL,QL</sup>	
meclizine (generic Antivert)	COMPRO (prochlorperazine)	
metoclopramide (generic Reglan)	doxylamine/pyridoxine (generic Diclegis) <sup>CL,QL</sup>	
phosphoric acid/dextrose/fructose <b>SOLUTION</b> (generic Emetrol)	metoclopramide ODT (generic Metozolv ODT)	
prochlorperazine, oral (generic Compazine)	prochlorperazine <b>SUPPOSITORY</b> (generic Compazine)	
promethazine <b>TABLET</b> (generic Phenergan)	promethazine <b>SUPPOSITORY</b> 50mg	
promethazine <b>SUPPOSITORY</b> 12.5mg, 25mg	scopolamine <b>TRANSDERMAL</b>	
TRANSDERM-SCOP (scopolamine)	trimethobenzamide <b>TABLET</b> (generic Tigan)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIFUNGALS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
clotrimazole (mucous membrane, troche) fluconazole <b>SUSPENSION, TABLET</b> (generic Diflucan) griseofulvin <b>SUSPENSION</b> griseofulvin microsize <b>TABLET</b> nystatin <b>SUSPENSION, TABLET</b> terbinafine (generic Lamisil)	BREXAFEMME (ibrexafungerp) <sup>QL,NR</sup> CRESEMBA (isavuconazonium) <sup>CL</sup> flucytosine (generic Ancobon) <sup>CL</sup> griseofulvin ultramicrosize (generic GRIS-PEG) itraconazole (generic Sporanox) <sup>CL</sup> ketoconazole (generic Nizoral) nystatin <b>POWDER</b> ONMEL (itraconazole) posaconazole (generic Noxafil) <sup>AL,CL</sup> TOLSURA (itraconazole) <sup>CL</sup> voriconazole (generic VFEND) <sup>CL</sup>	<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed a trial of TWO diagnosis-appropriate preferred agents within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>• <b>Cresemba®</b>: Approved for diagnosis of invasive aspergillosis or invasive mucormycosis</li> <li>• <b>Flucytosine</b>: Approved for diagnosis of:                             <ul style="list-style-type: none"> <li>Candida: Septicemia, endocarditis, UTIs</li> <li>Cryptococcus: Meningitis, pulmonary infections</li> </ul> </li> <li>• <b>Noxafil®</b>: No trial for diagnosis of Neutropenia Myelodysplastic Syndrome (MDS), Neutropenic Acute Myeloid Leukemia (AML), Neutropenic hematologic malignancies, Graft vs. Host disease (GVHD), Immunosuppression secondary to hematopoietic stem cell transplant</li> <li>• <b>Noxafil® Suspension</b>: Oropharyngeal/esophageal candidiasis refractory to itraconazole and/or fluconazole</li> <li>• <b>Onmel®</b>: Requires trial and failure or contraindication to terbinafine</li> <li>• <b>Sporanox®/itraconazole</b>: Approved for diagnosis of Aspergillosis, Blastomycosis, Histoplasmosis, Onychomycosis due to terbinafine-resistant dermatophytes, Oropharyngeal/ esophageal candidiasis refractory to fluconazole</li> <li>• <b>Sporanox®</b>: Requires trial and failure of generic itraconazole</li> <li>• <b>Sporanox® Liquid</b>: Clinical reason solid oral cannot be used</li> <li>• <b>Tolsura</b>: Approved for diagnosis of Aspergillosis, Blastomycosis, and Histoplasmosis and requires a trial and failure of generic itraconazole</li> <li>• <b>Vfend®</b>: No trial for diagnosis of Myelodysplastic Syndrome (MDS), Neutropenic Acute Myeloid Leukemia (AML), Graft vs. Host disease (GVHD), Candidemia (candida krusei), Esophageal Candidiasis, Blastomycosis, <i>S. apiospermum</i> and <i>Fusarium spp.</i>, Oropharyngeal/esophageal candidiasis refractory to fluconazole</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIFUNGALS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ANTIFUNGAL</b>		
clotrimazole <b>CREAM</b> (generic Lotrimin) RX, OTC clotrimazole <b>SOLN</b> OTC ketoconazole <b>CREAM, SHAMPOO</b> (generic Nizoral) LAMISIL (terbinafine) <b>SPRAY</b> OTC LAMISIL AT <b>CREAM</b> (terbinafine) OTC miconazole <b>CREAM, POWDER</b> OTC nystatin terbinafine OTC (generic Lamisil AT) tolnaftate <b>POWDER, CREAM, POWDER</b> OTC (generic Tinactin)	ALEVAZOL (clotrimazole) OTC ciclopirox <b>CREAM, GEL, SUSPENSION</b> (generic Ciclodan, Loprox) ciclopirox <b>NAIL LACQUER</b> (generic Penlac) ciclopirox <b>SHAMPOO</b> (generic Loprox) clotrimazole <b>SOLUTION</b> RX (generic Lotrimin) DESENEXT <b>POWDER</b> OTC (miconazole) econazole (generic Spectazole) ERTACZO (sertaconazole) EXELDERM (sulconazole) FUNGOID OTC JUBLIA (efinaconazole) <i>tavorole SOLUTION (generic Kerydin)<sup>NR</sup></i> ketoconazole <b>FOAM</b> (generic Extina, Ketodan) LAMISIL AT <b>GEL, SPRAY</b> (terbinafine) OTC LOPROX (ciclopirox) <b>SUSPENSION, SHAMPOO, CREAM</b> LOTRIMIN AF <b>CREAM</b> OTC (clotrimazole) LOTRIMIN ULTRA (butenafine) luliconazole (generic Luzu) MENTAX (butenafine) miconazole OTC <b>OINTMENT, SPRAY</b> miconazole/zinc oxide/petrolatum (generic Vusion) naftifine <b>CREAM, GEL</b> (generic Naftin) oxiconazole (generic Oxistat) salicylic acid (generic Bensal HP) <i>tavorole SOLUTION (generic Kerydin)</i> tolnaftate <b>SPRAY</b> , OTC	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class within the last 6 months</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Extina:</b> Requires trial and failure or contraindication to other ketoconazole forms</li> <li><b>Jublia:</b> Approved diagnoses include Onychomycosis of the toenails due to <i>T.rubrum</i> OR <i>T. Mentagrophytes</i></li> <li><b>ciclopirox nail lacquer:</b> No trial required in diabetes, peripheral vascular disease (PVD), immunocompromised OR contraindication to oral terbinafine</li> </ul>
<b>ANTIFUNGAL/STEROID COMBINATIONS</b>		
clotrimazole/betamethasone <b>CREAM</b> (generic Lotrisone) <i>nystatin/triamcinolone (generic Mycolog)</i> <b>CREAM, OINT</b>	clotrimazole/betamethasone <b>LOTION</b> (generic Lotrisone)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTI-HISTAMINES, MINIMALLY SEDATING

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
cetirizine <b>TABLET, SOLUTION (Rx only)</b> (generic for Zyrtec) loratadine <b>TABLET, SOLUTION</b> (generic for Claritin) levocetirizine <b>TABLET</b> (generic for Xyzal)	cetirizine <b>CHEWABLE</b> (generic for Zyrtec) cetirizine <b>SOLUTION (OTC)</b> desloratadine (generic for Clarinex) desloratadine ODT (generic for Clarinex Reditabs) fexofenadine (generic for Allegra) fexofenadine 180mg (generic for Allegra 180mg) <sup>QL</sup> levocetirizine (generic for Xyzal) <b>SOLUTION</b> loratadine <b>CAPSULE, CHEWABLE, ODT</b> (generic for Claritin Reditabs)	<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed TWO preferred agents within this drug class</li> <li>• Combination products not covered – individual products may be covered</li> </ul>

## ANTI-HYPERTENSIVES, SYMPATHOLYTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
CATAPRES-TTS (clonidine) clonidine <b>TABLET</b> (generic for Catapres) guanfacine (generic for Tenex) methyldopa	clonidine <b>TRANSDERMAL</b> methyldopa/hydrochlorothiazide	<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed a 30-day trial with ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANTIHYPERURICEMICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
allopurinol (generic for Zyloprim) MITIGARE (colchicine) probenecid probenecid/colchicine (generic for Col-Probenecid)	colchicine <b>TABLET</b> (generic for Colcrys) <sup>CL</sup> colchicine <b>CAPSULE</b> (generic for Mitigare) febuxostat (generic for Uloric) <sup>CL</sup> <b>GLOPERBA SOLN</b> (colchicine) <sup>CL, QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> <li><b>colchicine tablet</b><sup>®</sup>: Approved without trial for familial Mediterranean fever OR pericarditis</li> <li><b>Gloperba</b>: Approved for documented swallowing disorder</li> <li><b>Uloric</b><sup>®</sup>: Clinical reason why allopurinol cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIMIGRAINE AGENTS, OTHER

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<p>AJOVY (fremanezumab-vfrm)<sup>CL, QL</sup> <b>PEN, Autoinjector, Autoinjector 3-pack<sup>NR</sup></b></p> <p>EMGALITY 120 mg/mL (galcanezumab-gnlm)<sup>CL, QL</sup> <b>PEN, SYRINGE</b></p> <p>UBRELVY (ubrogepant)<sup>AL, CL, QL</sup> <b>TABLET</b></p>	<p>AIMOVIG (erenumab-aooe)<sup>CL, QL</sup></p> <p>CAFERGOT (ergotamine/caffeine)</p> <p>CAMBIA (diclofenac potassium)</p> <p>dihydroergotamine mesylate <b>NASAL</b></p> <p>ELYXYB (celecoxib)<sup>AL, NR, QL</sup> <b>SOLN</b></p> <p>EMGALITY 100 mg (galcanezumab-gnlm)<sup>CL, QL</sup> <b>SYRINGE</b></p> <p>ERGOMAR <b>SUBLINGUAL</b> (ergotamine tartrate)</p> <p>MIGERGOT (ergotamine/caffeine) <b>RECTAL</b></p> <p>MIGRANAL (dihydroergotamine) <b>NASAL</b></p> <p>NURTEC ODT (rimegepant)<sup>AL, CL, QL</sup></p> <p>QULIPTA (atogepant)<sup>AL, NR, QL</sup></p> <p>REYVOW (lasmiditan)<sup>AL, CL, QL</sup> <b>TABLET</b></p> <p><b>TRUDHESA (dihydroergotamine mesylate)<sup>AL, NR, QL</sup> NASAL</b></p>	<ul style="list-style-type: none"> <li>All acute treatment agents will be approved for patients who have a failed trial or contraindication of a triptan.</li> <li>In addition, all non-preferred agents will require a failed trial or contraindication of a preferred agent of the same indication</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Cambia<sup>®</sup></b>: Requires diagnosis of migraine and documentation of why solid dosing forms not appropriate</li> <li><b>Emgality 120mg</b> is recommended dosing for Migraine, <i>Emgality 100mg is recommended dosing for Episodic Cluster Headache</i></li> <li><b>Aimovig, Ajoy and Emgality 120mg</b>: Require <math>\geq 4</math> migraines per month for <math>\geq 3</math> months and has tried and failed a <math>\geq 1</math> month trial of two medications listed in the 2012 American Academy of Neurology/American Headache Society guidelines (examples include: antidepressants (amitriptyline, venlafaxine), Beta blockers (propranolol, metoprolol, timolol, atenolol), anti-epileptics (valproate, topiramate), ACE/ARB (lisinopril, candesartan)</li> <li>In addition, <b>Aimovig</b> requires a trial of Emgality 120mg or Ajoy or clinical, patient specific reason that a preferred agent cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANTIMIGRAINE AGENTS, TRIPTANS<sup>QL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ORAL</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ALL preferred agents within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Sumavel<sup>®</sup> Dosepro:</b> Requires clinical reason sumatriptan injection cannot be used</li> <li><b>Onzetra, Zembrace:</b> approved for patients who have failed ALL preferred agents</li> </ul>
rizatriptan (generic Maxalt) rizatriptan ODT (generic Maxalt MLT) sumatriptan	almotriptan (generic Axert) eletriptan (generic Relpax) frovatriptan (generic Frova) IMITREX (sumatriptan) naratriptan (generic Amerge) RELPAX (eletriptan) <sup>QL</sup> sumatriptan/naproxen (generic Treximet) zolmitriptan (generic Zomig/Zomig ZMT)	
<b>NASAL</b>		
IMITREX (sumatriptan)	ONZETRA XSAIL (sumatriptan) sumatriptan (generic Imitrex Nasal) TOSYMRA (sumatriptan) zolmitriptan ( <i>generic for Zomig</i> ) ZOMIG (zolmitriptan)	
<b>INJECTABLE</b>		
sumatriptan <b>KIT, SYRINGE, VIAL</b>	IMITREX (sumatriptan) <b>INJECTION</b> SUMAVEL DOSEPRO (sumatriptan) ZEMBRACE SYMTOUCH (sumatriptan)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANTIPARASITICS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
NATROBA (spinosad) permethrin 1% OTC (generic Nix) permethrin 5% RX (generic Elimite) pyrethrin/piperonyl butoxide (generic RID, A-200)	CROTAN (crotamiton) LOTION EURAX (crotamiton) <b>CREAM,</b> <b>LOTION</b> <i>ivermectin (generic Sklice) LOTION</i> <sup>NR</sup> lindane malathion (generic Ovide) SKLICE (ivermectin) spinosad (generic Natroba) VANALICE (piperonyl butoxide/pyrethrins)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIPARKINSON'S AGENTS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ANTICHOLINERGICS</b>		
benztropine (generic for Cogentin) trihexyphenidyl (generic for Artane)		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed ONE preferred agents within this drug class</li> </ul>
<b>COMT INHIBITORS</b>		
	entacapone (generic for Comtan) tolcapone (generic for Tasmar)	<p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Carbidopa/Levodopa ODT:</b> Approved for documented swallowing disorder</li> <li><b>COMT Inhibitors:</b> Approved if using as add-on therapy with levodopa-containing drug</li> <li><b>Gocovri:</b> Required diagnosis of Parkinson's disease and had trial of or is intolerant to amantadine AND must be used as an add-on therapy with levodopa-containing drug</li> <li><b>Inbrija:</b> Approval upon diagnosis of Parkinson's disease and concurrent treatment with carbidopa/levodopa agent</li> <li><b>Neupro®:</b> <ul style="list-style-type: none"> <li>For Parkinsons: Clinical reason required why preferred agent cannot be used</li> <li>For Restless Leg (RLS): Requires trial OR Contraindication to ropinirole AND pramipexole</li> </ul> </li> <li><b>Nourianz:</b> <i>Approval upon diagnosis of Parkinson's disease and concurrent treatment with carbidopa/levodopa agent</i></li> <li><b>Osmolex ER:</b> Required diagnosis of Parkinson's disease or drug-induced extrapyramidal reactions and had trial of or is intolerant to amantadine IR</li> <li><b>Pramipexole ER:</b> Required diagnosis of Parkinson's along with preferred agent trial</li> <li><b>Ropinerole ER:</b> Required diagnosis of Parkinson's along with preferred agent trial</li> <li><b>Zelapar®:</b> Approved for documented swallowing disorder</li> </ul>
<b>DOPAMINE AGONISTS</b>		
pramipexole (generic for Mirapex) ropinirole (generic for Requip)	bromocriptine (generic for Parlodel) ropinirole ER (generic for Requip ER) <sup>CL</sup> NEUPRO (rotigotine) <sup>CL</sup> pramipexole ER (generic for Mirapex ER) <sup>CL</sup> ropinirole ER (generic for Requip XL) <sup>CL</sup>	
<b>MAO-B INHIBITORS</b>		
selegiline <b>CAPSULE, TABLET</b> (generic for Eldepryl)	rasagiline (generic for Azilect) <sup>QL</sup> XADAGO (safinamide) ZELAPAR (selegiline) <sup>CL</sup>	
<b>OTHER ANTIPARKINSON'S DRUGS</b>		
amantadine <b>CAPSULE, SYRUP TABLET</b> (generic for Symmetrel) carbidopa/levodopa (generic for Sinemet) carbidopa/levodopa ER (generic for Sinemet CR) levodopa/carbidopa/entacapone (generic for Stalevo)	APOKYN (apomorphine) <b>SUB-Q</b> carbidopa (generic for Lodosyn) carbidopa/levodopa ODT (generic for Parcopa) DHIVY (carbidopa/levodopa) <sup>NR,QL</sup> DUOPA (carbidopa/levodopa) GOCOVRI (amantadine) <sup>QL</sup> INBRIJA (levodopa) INHALER <sup>CL,QL</sup> KYNMOBI (apomorphine) <sup>QL</sup> , <b>KIT, SUBLINGUAL</b> NOURIANZ (istradefylline) <sup>CL,QL</sup> OSMOLEX ER (amantadine) <sup>QL</sup> RYTARY (carbidopa/levodopa) STALEVO (ledopa/carbidopa/entacapone)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ANTIPSORIATICS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
acitretin (generic for Soriatane)	methoxsalen (generic for Oxsoralen-Ultra) SORIATANE (acitretin)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with THE preferred agent within this drug class</li> <li>Trial of acitretin (Pregnancy category X) not required in pregnancy or while attempting or planning pregnancy</li> </ul>

## ANTIPSORIATICS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
calcipotriene <b>CREAM, OINTMENT, SOLUTION,</b>	calcitriol (generic for Vectical) calcipotriene/betamethasone <b>OINTMENT</b> (generic for Taclonex) <i>calcipotriene/betamethasone <b>SUSP</b> (generic for Taclonex Scalp)</i> CALCITRENE (calcipotriene) DOVONEX <b>CREAM</b> (calcipotriene) DUOBRII (halobetasol prop/tazarotene) ENSTILAR (calcipotriene/betamethasone) SORILUX (calcipotriene)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ANTIVIRALS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ANTI-HERPETIC DRUGS</b>		
acyclovir (generic Zovirax) famciclovir (generic Famvir) valacyclovir (generic Valtrex)	acyclovir (generic for Zovirax) <sup>CL</sup> <b>SUSPENSION</b> SITAVIG (acyclovir buccal) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 10-day trial of ONE preferred agent within the same group</li> </ul>
<b>ANTI-INFLUENZA DRUGS</b>		
oseltamivir (generic Tamiflu) <sup>QL</sup>	rimantadine (generic Flumadine) RELENZA (zanamivir) <sup>QL</sup> TAMIFLU (oseltamivir) <sup>QL</sup> XOFLUZA (baloxavir marboxil) <sup>AL,CL,QL</sup>	<p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Acyclovir Susp:</b> Prior authorization NOT required for children ≤ 12 years old</li> <li><b>Sitavig®:</b> Approved for recurrent herpes labialis (cold sores) in immunocompetent adults</li> <li><b>Xofluza:</b> Requires clinical, patient specific reason that a preferred agent cannot be used</li> </ul>

## ANTIVIRALS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
acyclovir <b>OINTMENT</b>	acyclovir CREAM, (generic Zovirax) DENA VIR (penciclovir) XERESE (acyclovir/hydrocortisone)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred ORAL Antiviral agent</li> </ul>

## ANXIOLYTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
alprazolam <b>TABLET</b> (generic for Xanax) buspirone (generic for Buspar) chlordiazepoxide diazepam <b>TABLET, SOLUTION</b> (generic for Valium) lorazepam <b>INTENSOL, TABLET</b> (generic for Ativan)	alprazolam ER (generic for Xanax XR) alprazolam ODT alprazolam <b>INTENSOL</b> <sup>CL</sup> clorazepate (generic for Tranxene-T) diazepam <b>INTENSOL</b> <sup>CL</sup> <i>lorazepam</i> <b>ORAL SYRINGE</b> <sup>NR</sup> LOREEV XR (lorazepam) <sup>AL,NR</sup> meprobamate oxazepam	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with TWO preferred agents within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Diazepam Intensol®:</b> Requires clinical reason why diazepam solution cannot be used</li> <li><b>Alprazolam Intensol®:</b> Requires trial of diazepam solution OR lorazepam Intensol®</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## BETA BLOCKERS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BETA BLOCKERS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed TWO diagnosis-appropriate preferred agents within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Bystolic®</b>: Only ONE trial is required with Diagnosis of Obstructive Lung Disease</li> <li><b>Coreg CR®</b>: Requires clinical reason generic IR product cannot be used</li> <li><b>Hemangeol®</b>: Covered for diagnosis of Proliferating Infantile Hemangioma</li> <li><b>Sotylize®</b>: Covered for diagnosis of life –threatening ventricular arrhythmias OR maintenance of normal sinus rhythm in highly symptomatic atrial fibrillation/flutter (AFIB/AFL) Requires clinical reason generic sotalol cannot be used</li> </ul>
atenolol (generic Tenormin) atenolol/chlorthalidone (generic Tenoretic) bisoprolol (generic Zebeta) bisoprolol/HCTZ (generic Ziac) metoprolol (generic Lopressor) metoprolol ER (generic Toprol XL) propranolol (generic Inderal) propranolol ER (generic Inderal LA)	acebutolol (generic Sectral) betaxolol (generic Kerlone) BYSTOLIC (nebivolol) HEMANGEOL (propranolol) <b>SOLUTION</b> INDERAL/INNOPRAN XL (propranolol ER) KAPSPARGO SPRINKLE (metoprolol ER) LEVATOL (penbutolol) metoprolol/HCTZ (generic Lopressor HCT) nadolol (generic Corgard) nadolol/bendroflumethiazide nebivolol (generic Bystolic) <sup>NR</sup> pindolol (generic Viskin) propranolol/HCTZ (generic Inderide) timolol (generic Blocadren) TOPROL XL (metoprolol ER)	
<b>BETA- AND ALPHA-BLOCKERS</b>		
carvedilol (generic Coreg) labetalol (generic Trandate)	carvedilol ER (generic Coreg CR)	
<b>ANTIARRHYTHMIC</b>		
sotalol (generic Betapace)	SOTYLIZE (sotalol)	

## BILE SALTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ursodiol <b>CAPSULE</b> 300mg (generic for Actigall) ursodiol 250mg <b>TABLET</b> (generic for URSO) ursodiol 500mg <b>TABLET</b> (generic for URSO FORTE)	<b>BYLVAY (odevixibat)<sup>NR</sup> CAP, PELLETT</b> CHENODAL (chenodiol) CHOLBAM (cholic acid) <b>LIVMARLI (maralixibat) SOLN<sup>AL,NR</sup></b> OCALIVA (obeticholic acid) <b>RELTONE (ursodiol 200mg,400mg) CAP<sup>NR</sup></b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## BLADDER RELAXANT PREPARATIONS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
Oxybutynin IR, ER (generic Ditropan/Ditropan XL) solifenacin (generic Vesicare) TOVIAZ (fesoterodine ER)	darifenacin ER (generic Enablex) GELNIQUE (oxybutynin) GEMTESA (vibegron) <sup>AL,NR,QL</sup> flavoxate MYRBETRIQ <b>TAB, SUSP</b> <sup>AL,NR,QL</sup> (mirabegron) OXYTROL (oxybutynin) tolterodine IR, ER (generic Detrol/ Detrol LA) trospium IR, ER (generic Sanctura/ Sanctura XR) VESICARE (solifenacin) VESICARE <b>LS SUSP</b> (solifenacin succinate) <sup>AL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Myrbetriq<sup>®</sup></b>: Covered without trial in contraindication to anticholinergic agents</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## BONE RESORPTION SUPPRESSION AND RELATED DRUGS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BISPHOSPHONATES</b>		<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within the same group</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>• <b>Actonel® Combinations:</b> Covered as individual agents without prior authorization</li> <li>• <b>Atelvia DR®:</b> Requires clinical reason alendronate cannot be taken on an empty stomach</li> <li>• <b>Binosto®:</b> Requires clinical reason why alendronate tablets OR Fosamax® solution cannot be used</li> <li>• <b>Etidronate disodium:</b> Trial not required for diagnosis of heterotrophic ossification</li> <li>• <b>Forteo®:</b> Covered for high risk of fracture High risk of fracture:               <ul style="list-style-type: none"> <li>• BMD -3 or worse</li> <li>• Postmenopausal women with history of non-traumatic fractures</li> <li>• Postmenopausal women with 2 or more clinical risk factors                   <ul style="list-style-type: none"> <li>○ Family history of non-traumatic fractures</li> <li>○ DXA BMD T-score ≤ -2.5 at any site</li> <li>○ Glucocorticoid use ≥ 6 months at 7.5 dose of prednisolone equivalent</li> <li>○ Rheumatoid Arthritis</li> </ul> </li> <li>• Postmenopausal women with BMD T-score ≤ -2.5 at any site with any clinical risk factors                   <ul style="list-style-type: none"> <li>○ More than 2 units of alcohol per day</li> <li>○ Current smoker</li> </ul> </li> <li>• Men with primary or hypogonadal osteoporosis</li> <li>• Osteoporosis associated with sustained systemic glucocorticoid therapy</li> <li>• Trial of calcitonin-salmon not required</li> <li>• Maximum of 24 months treatment per lifetime</li> </ul> </li> </ul>
alendronate (generic Fosamax) <b>TABLET</b> ibandronate (generic Boniva) <sup>QL</sup>	alendronate <b>SOLUTION</b> (generic Fosamax) <sup>QL</sup> ATELVIA DR (risedronate) BINOSTO (alendronate) etidronate disodium (generic Didronel) FOSAMAX PLUS D <sup>QL</sup> risedronate (generic Actonel) <sup>QL</sup>	
<b>OTHER BONE RESORPTION SUPPRESSION AND RELATED DRUGS</b>		
calcitonin-salmon <b>NASAL</b> raloxifene (generic Evista) teriparatide (generic Forteo) <sup>CL,QL</sup>	EVISTA (raloxifene) FORTEO (teriparatide) <sup>CL,QL</sup> TYMLOS (abaloparatide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## BPH (BENIGN PROSTATIC HYPERPLASIA) TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ALPHA BLOCKERS</b>		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>
alfuzosin (generic Uroxatral) doxazosin (generic Cardura) tamsulosin (generic Flomax) terazosin (generic Hytrin)	CARDURA XL (doxazosin) silodosin (generic Rapaflo)	
<b>5-ALPHA-REDUCTASE (5AR) INHIBITORS</b>		Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Alfuzosin/dutasteride/finasteride</b> <ul style="list-style-type: none"> <li>Covered for males only</li> </ul> </li> <li><b>Cardura XL®</b>: Requires clinical reason generic IR form cannot be used</li> <li><b>Flomax®</b>: Females covered for a 7 day supply with diagnosis of acute kidney stones</li> <li><b>Jalyn®</b>: Requires clinical reason why individual agents cannot be used</li> </ul>
dutasteride (generic for Avodart) finasteride (generic for Proscar)	dutasteride/tamsulosin (generic for Jalyn)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## BRONCHODILATORS, BETA AGONIST

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria	
<b>INHALERS – Short Acting</b>			
PROAIR HFA (albuterol) <b>albuterol HFA (generic for ProAir HFA)</b>	albuterol HFA (Proventil HFA, Ventolin HFA) levalbuterol HFA (generic for Xopenex HFA) <i>PROAIR DIGIHALER (albuterol)</i> PROAIR RESPICLICK (albuterol) PROVENTIL HFA (albuterol)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Xopenex®</b>: Covered for cardiac diagnoses or side effect of tachycardia with albuterol product</li> </ul>	
<b>INHALERS – Long Acting</b>			
SEREVENT (salmeterol)	ARCAPTA NEOHALER (indacaterol) STRIVERDI RESPIMAT (olodaterol)		
<b>INHALATION SOLUTION</b>			
albuterol (2.5mg/3ml premix or 2.5mg/0.5ml) albuterol 100 mg/20 mL albuterol low dose (0.63mg/3ml & 1.25mg/3ml)	<b>arformoterol tartrate (generic Brovana)</b> BROVANA (arformoterol) <b>formoterol fumarate (generic Perforomist)</b> levalbuterol (generic for Xopenex) PERFOROMIST (formoterol)		
<b>ORAL</b>			
albuterol <b>SYRUP</b>	albuterol <b>TABLET</b> albuterol ER (generic for Vospire ER) metaproterenol (formerly generic for Alupent) terbutaline (generic for Brethine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## CALCIUM CHANNEL BLOCKERS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>SHORT-ACTING</b>		<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>• <b>Nifedipine:</b> May be approved without trial for diagnosis of Preterm Labor or Pregnancy Induced Hypertension (PIH)</li> <li>• <b>Nimodipine:</b> Covered without trial for diagnosis of subarachnoid hemorrhage</li> <li>• <b>Katerzia:</b> May be approved with documented swallowing difficulty</li> </ul>
<b>Dihydropyridines</b>		
	isradipine (generic Dynacirc) nicardipine (generic Cardene) nifedipine (generic Procardia) nimodipine (generic Nimotop) NYMALIZE (nimodipine) <b>SOLUTION</b>	
<b>Non-dihydropyridines</b>		
diltiazem (generic Cardizem) verapamil (generic Calan/Isoptin)		
<b>LONG-ACTING</b>		
<b>Dihydropyridines</b>		
amlodipine (generic Norvasc) nifedipine ER (generic Procardia XL/ Adalat CC)	felodipine ER (generic Plendil) KATERZIA (amlodipine) <sup>QL</sup> <b>SUSP</b> nisoldipine (generic Sular)	
<b>Non-dihydropyridines</b>		
diltiazem ER (generic Cardizem CD) verapamil ER <b>TABLET</b>	CALAN SR (verapamil) diltiazem ER (generic Cardizem LA) MATZIM LA (diltiazem ER) TIAZAC (diltiazem) verapamil ER <b>CAPSULE</b> verapamil 360mg <b>CAPSULE</b> verapamil ER (generic Verelan PM)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## CEPHALOSPORINS AND RELATED ANTIBIOTICS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS</b>		
amoxicillin/clavulanate <b>TABLETS, SUSPENSION</b>	amoxicillin/clavulanate <b>CHEWABLE</b> amoxicillin/clavulanate ER (generic Augmentin XR) AUGMENTIN (amoxicillin/clavulanate) <b>SUSPENSION, TABLET</b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 3-day trial of ONE preferred agent within the same group</li> </ul>
<b>CEPHALOSPORINS – First Generation</b>		
cefadroxil <b>CAPSULE, SUSPENSION</b> (generic Duricef) cephalexin <b>CAPSULE, SUSPENSION</b> (generic Keflex)	cefadroxil <b>TABLET</b> (generic Duricef) cephalexin <b>TABLET</b>	
<b>CEPHALOSPORINS – Second Generation</b>		
cefprozil (generic Cefzil) cefuroxime <b>TABLET</b> (generic Ceftin)	cefactor (generic Ceclor) CEFTIN (cefuroxime) <b>TABLET, SUSPENSION</b>	
<b>CEPHALOSPORINS – Third Generation</b>		
cefdinir (generic Omnicef)	cefixime <b>CAPSULE, SUSPENSION</b> (generic Suprax) cefepodoxime (generic Vantin) SUPRAX <b>CAPSULE, CHEWABLE TAB, SUSPENSION, TABLET</b> (cefixime)	

## COLONY STIMULATING FACTORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
NEUPOGEN (filgrastim) <b>VIAL</b>	GRANIX (tbo-filgrastim) NEUPOGEN <b>DISP SYR</b> (filgrastim) NIVESTYM <b>SYR, VIAL</b> (filgrastim-aafi) <b>Nyvepria (pegfilgrastim-apgf)</b> ZARXIO (filgrastim-sndz) ZIEXTENZO <b>SYR</b> (pegfilgrastim-bmez)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## CONTRACEPTIVES, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<p>All reviewed agents are recommended preferred at this time <i>Only those products for review are listed.</i> Brand name products may be subject to Maximum Allowable Cost (MAC) pricing or require substitution with a generic equivalent</p> <p>Specific agents can be looked up using the Drug Look-up Tool at: <a href="https://druglookup.fhsc.com/druglookupweb/?client=nestate">https://druglookup.fhsc.com/druglookupweb/?client=nestate</a></p>	<p><i>DOLISHALE (ethinyl estradiol/levonorgestrel)<sup>NR</sup></i> <i>NEXTSTELLIS (drospirenone/estetrol)<sup>NR</sup></i> <i>TAYSOFY (norethindrone/ethinyl estradiol/iron)<sup>NR</sup></i> <i>TYBLUME (levonorgestrel/ ethinyl estradiol)<sup>NR</sup></i></p>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) AGENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria	
<b>INHALERS</b>			
ANORO ELLIPTA (umeclidinium/vilanterol) ATROVENT HFA (ipratropium) COMBIVENT RESPIMAT (albuterol/ ipratropium) SPIRIVA (tiotropium) STIOLTO RESPIMAT (tiotropium/olodaterol)	BEVESPI AEROSPHERE (glycopyrolate/formoterol) DUAKLIR PRESSAIR (aclidinium br and formoterol fum) INCRUSE ELIPTA (umeclidinium) SEEBRI NEOHALER (glycopyrolate) SPIRIVA RESPIMAT (tiotropium) TUDORZA PRESSAIR (aclidinium br) UTIBRON NEOHALER (indacaterol/glycopyrolate)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class OR Patient specific documentation of inability to use traditional inhaler device.</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Daliresp®:</b> Covered for diagnosis of severe COPD associated with chronic bronchitis Requires trial of a bronchodilator Requires documentation of one exacerbation in last year upon initial review</li> </ul>	
<b>INHALATION SOLUTION</b>			
albuterol/ipratropium (generic for Duoneb) ipratropium <b>SOLUTION</b> (generic for Atrovent)	LONHALA (glycopyrrolate inhalation soln) YUPELRI (revefenacin)		
<b>ORAL AGENT</b>			
	DALIRESP (roflumilast) <sup>CL, QL</sup>		

## COUGH AND COLD, OPIATE COMBINATION

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
	guaifenesin/codeine <b>LIQUID</b> hydrocodone/homatropine <b>SYRUP</b> promethazine/codeine <b>SYRUP</b> promethazine/phenylephrine/codeine <b>SYRUP</b> pseudoephedrine/codeine/ guaifenesin (generic for Lortuss EX, Tusnel C, Virtussin DAC)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE dextromethorphan product</li> <li>All codeine or hydrocodone containing cough and cold combinations are limited to <math>\geq 18</math> years of age</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## CYSTIC FIBROSIS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
	<p><i>BRONCHITOL (mannitol)<sup>AL,CL,QL</sup></i>  <b>KALYDECO PACKET, TABLET</b>  <i>(ivacaftor)<sup>QL, AL</sup></i>  <b>ORKAMBI (lumacaftor/ivacaftor)</b>  <b>PACKET, TABLET<sup>QL, AL</sup></b>  <b>SYMDEKO (tezacaftor/ivacaftor)<sup>QL, AL</sup></b>  <b>TRIKAFTA (elexacaftor, tezacaftor,</b>  <b>ivacaftor)<sup>AL, CL</sup></b></p>	<p><b>Drug-specific criteria:</b></p> <ul style="list-style-type: none"> <li><b>Bronchitol:</b> Approved for diagnosis of CF and documentation that the patient has passed the BRONCHITOL Tolerance Test</li> <li><b>Kalydeco®:</b> Diagnosis of CF and documentation of the drug-specific, FDA-approved mutation of CFTR gene</li> <li><b>Orkambi®:</b> Diagnosis of CF and documentation of presence of two copies of the F580del mutation (homozygous) of CFTR gene</li> <li><b>Symdeko:</b> Diagnosis of CF and documentation of the drug specific, FDA approved mutation of CFTR gene.</li> <li><b>Trikafta:</b> Diagnosis of CF and documentation of at least one F508del mutation in the CFTR gene</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## CYTOKINE & CAM ANTAGONISTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<p>ENBREL (etanercept) <b>KIT, MINI CART, PEN, SYR, VIAL</b><sup>QL</sup></p> <p>HUMIRA (adalimumab)<sup>QL</sup></p> <p>OTEZLA (apremilast) <b>ORAL</b><sup>CL,QL</sup></p>	<p>ACTEMRA (tocilizumab) <b>SUB-Q</b></p> <p>ARCALYST (nilonacept)</p> <p>CIMZIA (certolizumab pegol)<sup>QL</sup></p> <p>COSENTYX (secukinumab)</p> <p>ENSPRYNG (satralizumab-mwge) <b>SUB-Q</b></p> <p>ILUMYA (tildrakizumab) SUB-Q</p> <p>KEVZARA (sarilumab) <b>SUB-Q, PEN, SYRINGE</b></p> <p>KINERET (anakinra)</p> <p>OLUMIANT (baricitinib) <b>ORAL</b><sup>CL,QL</sup></p> <p>ORENCIA (abatacept) <b>SUB-Q</b></p> <p>RINVOQ ER (upadacitinib)<sup>CL,QL</sup></p> <p>SILIQ (brodalumab)</p> <p>SIMPONI (golimumab)</p> <p>SKYRIZI (risankizamab-rzaa) <b>SYRINGE</b></p> <p><b>SKYRIZI PEN (risankizamab-rzaa)</b><sup>QL</sup></p> <p>STELARA (ustekinumab) <b>SUB-Q</b></p> <p>TALTZ (ixekizumab)<sup>AL</sup></p> <p>TREMFYA (guselkumab)<sup>QL</sup></p> <p>XELJANZ (tofacitinib) <b>ORAL, SOLN</b><sup>CL,QL</sup></p> <p>XELJANZ XR (tofacitinib) <b>ORAL</b><sup>CL,QL</sup></p>	<ul style="list-style-type: none"> <li>Preferred agents will be approved with FDA-approved indication – ICD-10 diagnosis code is required.</li> <li>Non-preferred agents will be approved for FDA-approved indications in patients who have failed a trial of ONE preferred agent within this drug class, or upon diagnosis for non-preferred agent with FDA-approved indication if no preferred agent has FDA approval for diagnosis.</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Otezla:</b> Requires a trial of Humira</li> <li><b>Olumiant:</b> Requires documentation of inadequate response or intolerance to methotrexate and an inadequate response to one or more TNF antagonist therapies.</li> <li><b>Rinvoq:</b> Requires documentation of inadequate response or intolerance to methotrexate</li> <li><b>Xeljanz, Xeljanz XR:</b> Requires documentation of inadequate response or intolerance to Tumor Necrosis Factor (TNF).</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## DIURETICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>SINGLE-AGENT PRODUCTS</b>		
amiloride <b>TABLET</b> bumetanide <b>TABLET</b> chlorothiazide <b>TABLET</b> chlorthalidone <b>TABLET</b> (generic Diuril) furosemide <b>SOLUTION, TABLET</b> (generic Lasix) hydrochlorothiazide <b>CAPSULE, TABLET</b> (generic Microzide) indapamide <b>TABLET</b> metolazone <b>TABLET</b> spironolactone <b>TABLET</b> (generic Aldactone) torsemide <b>TABLET</b>	CAROSPIR (spironolactone) <b>SUSPENSION</b> eplerenone <b>TABLET</b> (generic Inspra) ethacrynic acid <b>CAPSULE</b> (generic Edecrin) KERENDIA (finerenone) <b>TABLET</b> <sup>NR,QL</sup> methyclothiazide <b>TABLET</b> THALITONE (chlorthalidone) <b>TABLET</b> <sup>NR</sup> triamterene (generic Dyrenium)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of <b>TWO</b> preferred agents within this drug class</li> </ul>
<b>COMBINATION PRODUCTS</b>		
amiloride/HCTZ <b>TABLET</b> spironolactone/HCTZ <b>TABLET</b> (generic Aldactazide) triamterene/HCTZ <b>CAPSULE, TABLET</b> (generic Dyazide, Maxzide)		

## ENZYME REPLACEMENT, GAUCHERS DISEASE

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ZAVESCA (miglustat) <sup>CL</sup>	CERDELGA (eliglustat) miglustat (generic Zavesca)	<ul style="list-style-type: none"> <li>Non-preferred agents require clinical documentation why the preferred product within this drug class is not appropriate</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Zavesca:</b> Approved for mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option</li> </ul>

## EPINEPHRINE, SELF-INJECTED<sup>QL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
epinephrine (AUTHORIZED GENERIC for Epipen/ Epipen Jr.) <b>AUTOINJECTOR</b>	epinephrine (generic for Adrenaclick) epinephrine (generic for Epipen/ Epipen Jr.) <b>AUTOINJECTOR</b> EPIPEN (epinephrine) <b>AUTOINJ</b> EPIPEN JR. (epinephrine) <b>AUTOINJ</b> SYMJEPI (epinephrine) <b>PFS</b>	<ul style="list-style-type: none"> <li>Non-preferred agents require clinical documentation why the preferred product within this drug class is not appropriate</li> </ul> <p>Brand name product may be authorized in event of documented national shortage of generic product.</p>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## ERYTHROPOIESIS STIMULATING PROTEINS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
RETACRIT (EPOETIN ALFA-EPBX)	EPOGEN (rHuEPO) PROCRIT (rHuEPO)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

## FLUOROQUINOLONES, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ciprofloxacin <b>TABLET</b> (generic Cipro) levofloxacin <b>TABLET</b> (generic Levaquin)	BAXDELA (delafloxacin) ciprofloxacin ER ciprofloxacin <b>SUSPENSION</b> (generic Cipro) levofloxacin <b>SOLUTION</b> moxifloxacin (generic Avelox) ofloxacin	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 3-day trial of ONE preferred agent within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Baxdela:</b> Coverable with documented intolerance or failure of preferred MRSA agents (clindamycin, doxycycline, linezolid, sulfamethoxazole/trimethoprim)</li> <li><b>Ciprofloxacin/Levofloxacin Suspension:</b> Coverable with documented swallowing disorders</li> <li><b>Oflxacin:</b> Trial of preferred not required for diagnoses of Pelvic Inflammatory Disease OR Acute Epididymitis (non-gonorrhea)</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## GI MOTILITY, CHRONIC

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
AMITIZA (lubiprostone) <sup>AL, QL</sup> LINZESS (linaclotide) <sup>QL</sup> MOVANTIK (naloxegol oxalate) <sup>QL</sup>	alosetron (generic Lotronex) <i>lubiprostone (generic Amitiza)<sup>AL, QL</sup></i> MOTEGRITY (prucalopride succinate) RELISTOR (methylnaltrexone) <b>TABLET<sup>QL</sup></b> SYMPROIC (naldemedine) TRULANCE (plecanatide) <sup>QL</sup> VIBERZI (eluxodoline)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 30-day trial of ONE preferred agent within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Lotronex<sup>®</sup></b>: Covered for diagnosis of IBS Diarrhea Predominant type with trial and failure of loperamide AND diphenoxylate</li> <li><b>Relistor<sup>®</sup></b>: Covered for diagnosis of opioid-induced constipation in adults with chronic, non-cancer pain after trial of at least TWO OTC laxatives (senna, bisacodyl, etc.) and failure of Movantik</li> <li><b>Symproic</b>: Covered for diagnosis of opioid-induced constipation in adult patients with chronic non-cancer pain after trial on at least TWO OTC laxatives and failure of Movantik</li> <li><b>Trulance<sup>®</sup></b>: Covered for diagnosis of either chronic idiopathic constipation or IBS with constipation after trial of at least TWO OTC laxatives (senna, bisacodyl, etc.)</li> <li><b>Viberzi<sup>®</sup></b>: Covered for diagnosis of IBS Diarrhea Predominant type with trial and failure of loperamide AND diphenoxylate</li> </ul>

## GLUCAGON AGENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
BAQSIMI (glucagon) <sup>AL, QL</sup> <b>NASAL</b> GLUCAGON EMERGENCY (glucagon) <sup>QL</sup> <b>INJ KIT</b> (Lilly) glucagon <sup>QL</sup> <b>INJECTION</b> PROGLYCEM (diazoxide) <b>SUSP</b>	diazoxide <b>SUSP</b> (generic Proglycem) GLUCAGON EMERGENCY (glucagon) <sup>QL</sup> <b>INJ KIT</b> (Fresenius) GVOKE (glucagon) <sup>AL, QL</sup> <b>KIT<sup>NR</sup>, PEN,</b> <b>SYRINGE, VIAL<sup>NR</sup></b> <b>ZEGALOGUE (dasiglucagon)<sup>AL, NR</sup></b> <b>AUTO-INJECTOR. SYRINGE</b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## GLUCOCORTICIDS, INHALED

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>GLUCOCORTICIDS</b>		
ASMANEX (mometasone) <sup>QL,AL</sup> FLOVENT HFA (fluticasone) PULMICORT FLEXHALER (budesonide)	AEROSPAN (flunisolide) ALVESCO (ciclesonide) <sup>AL,CL</sup> <b>ARMONAIR DIGIHALER</b> (fluticasone) <sup>AL,QL</sup> ARMONAIR RESPICLICK (fluticasone) <sup>AL</sup> ARNUITY ELLIPTA (fluticasone) ASMANEX HFA (mometasone) <sup>CL,AL,QL</sup> FLOVENT DISKUS (fluticasone) QVAR (beclomethasone) QVAR Redihaler (beclomethasone)	<ul style="list-style-type: none"> <li>Non-preferred agents within the Glucocorticoids and Glucocorticoid/Bronchodilator Combo groups will be approved for patients who have failed a trial of TWO preferred agents within this drug class within the last 6 months</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>budesonide respules:</b> Covered without PA for age ≤ 8 years OR for diagnosis of eosinophilic esophagitis in patients ≥ 9 years, by GI biopsy or upper endoscopy. For other indications, must have failed a trial of two preferred agents within this drug class, within the last 6 months.</li> </ul>
<b>GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS</b>		
ADVAIR DISKUS (fluticasone/ salmeterol) <sup>QL</sup> ADVAIR HFA (fluticasone/salmeterol) <sup>QL</sup> DULERA (mometasone/formoterol) SYMBICORT (budesonide/ formoterol)	AIRDUO DIGIHALER (fluticasone/salmeterol) <sup>AL,QL</sup> BREO ELLIPTA (fluticasone/vilanterol) BREZTRI (budesonide/formoterol/ glycopyrrolate) <sup>QL</sup> Budesonide/formoterol (generic for Symbicort) fluticasone/salmeterol (generic for Advair Diskus) <sup>QL</sup> fluticasone/salmeterol (generic for Airduo Respiclick) TRELEGY ELLIPTA (fluticasone/ umeclidinium/vilanterol) WIXELA INHUB (generic for Advair Diskus) <sup>QL</sup>	
<b>INHALATION SOLUTION</b>		
	budesonide <b>RESPULES</b> (generic for Pulmicort)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## GLUCOCORTICOIDS, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
budesonide EC <b>CAPSULE</b> (generic for Entocort EC) dexamethasone <b>ELIXIR, SOLN</b> dexamethasone <b>TABLET</b> hydrocortisone <b>TABLET</b> methylprednisolone tablet (generic for Medrol) prednisolone <b>SOLUTION</b> prednisolone sodium phosphate prednisone <b>DOSE PAK</b> prednisone <b>TABLET</b>	<b>ALKINDI (hydrocortisone) GRANULES<sup>AL</sup></b> CORTEF (hydrocortisone) cortisone <b>TABLET</b> dexamethasone <b>INTENSOL</b> DEXPAK (dexamethasone) DXEVO (dexamethasone) EMFLAZA (deflazacort) <b>SUSPENSION, TABLET<sup>CL</sup></b> ENTOCORT EC (budesonide) methylprednisolone 8mg, 16mg, 32mg <b>ORTIKOS ER (budesonide)<sup>AL, QL</sup></b> PEDIAPRED (prednisolone sodium phosphate) prednisolone sodium phosphate (generic for Millipred/Veripred) prednisolone sodium phosphate <b>ODT</b> prednisone <b>SOLUTION</b> prednisone <b>INTENSOL</b> RAYOS DR (prednisone) <b>TABLET</b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agents within this drug class within the last 6 months</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Emflaza:</b> Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older</li> <li><b>Intensol Products:</b> Patient specific documentation of why the less concentrated solution is not appropriate for the patient</li> </ul>

## GROWTH HORMONES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
GENOTROPIN (somatropin) NORDITROPIN (somatropin)	HUMATROPE (somatropin) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) <b>SKYTROFA (lonapegsomatropin-tcgd)<sup>NR</sup></b> ZOMACTON (somatropin) ZORBTIVE (somatropin)	<a href="#">Growth Hormone PA Form</a> <a href="#">Growth Hormone Criteria</a>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## H. PYLORI TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
PYLERA (bismuth, metronidazole, tetracycline) <sup>QL</sup>	lansoprazole/amoxicillin/clarithromycin (generic Prevpac) <sup>QL</sup> OMECLAMOX-PAK (omeprazole, clarithromycin, amoxicillin) <sup>QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

## HAE TREATMENTS<sup>CL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
BERINERT (C1 esterase inhibitor, human) <b>INTRAVENOUS</b> HAEGARDA (C1 esterase inhibitor, human) <sup>AL,CL</sup> <b>SUB-Q</b> icatibant acetate (generic for FIRAZYR) <sup>AL</sup> <b>SUB-Q</b>	CINRYZE (C1 esterase inhibitor, human) <sup>AL,CL</sup> <b>INTRAVENOUS</b> FIRAZYR (icatibant acetate) <sup>AL</sup> <b>SUB-Q</b> ORLADEYO (berotralstat) <b>CAP</b> <sup>AL,QL</sup> RUCONEST (recombinant human C1 inhibitor) <sup>AL</sup> <b>INTRAVENOUS</b> TAKHZYRO (lanadelumab-flyo) <sup>AL,CL</sup> <b>SUB-Q</b>	<p style="text-align: center;"><a href="#">HAE Treatments PA Form</a></p> <ul style="list-style-type: none"> <li>All agents require documentation of diagnosis of Type I or Type II HAE and deficient or dysfunctional C1 esterase inhibitor enzyme. Concomitant use with ACE inhibitors, NSAIDs, or estrogen-containing products is contraindicated</li> <li>Non-preferred agents will be approved for patients who have a failed trial or a contraindication to ONE preferred agent within this drug class</li> </ul> <p>Drug-Specific Criteria</p> <ul style="list-style-type: none"> <li><b>Cinryze, Haegarda, Orladeyo, and Takhzyro</b>, require a history of two or more HAE attacks monthly, and trial and failure or contraindication to oral danazol</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HEMOPHILIA TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>FACTOR VIII</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> <li>▪ <i>Patients receiving a hemophilia agent which moved from preferred to non-preferred status on 1-21-21 will be allowed to continue same therapy</i></li> </ul>
ALPHANATE HELIXATE FS HUMATE-P NOVOEIGHT NUWIQ XYNTHA KIT, SOLOFUSE	ADVATE ADYNOVATE AFSTYLA ELOCTATE ESPEROCT HEMOPIL-M JIVI <sup>AL</sup> KOATE-DVI KIT KOATE-DVI VIAL KOGENATE FS KOVALTRY OBIZUR RECOMBINATE	
<b>FACTOR IX</b>		
ALPROLIX BENEFIX	ALPHANINE SD IDELVION IXINITY MONONINE PROFILNINE SD REBINYN RIXUBIS	
<b>FACTOR VIIa AND PROTHROMBIN COMPLEX-PLASMA DERIVED</b>		
NOVOSEVEN RT	FEIBA NF SEVENFACT <sup>AL</sup>	
<b>FACTOR X AND XIII PRODUCTS</b>		
COAGADEX CORIFACT	TRETTEN	
<b>VON WILLEBRAND PRODUCTS</b>		
WILATE	VONVENDI	
<b>BISPECIFIC FACTORS</b>		
HEMLIBRA		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HEPATITIS B TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
entecavir <b>TABLET</b>	adefovir dipivoxil BARACLUDE (entecavir) SOLUTION, <b>TABLET</b> EPIVIR HBV (lamivudine) <b>TABLET</b> , <b>SOLUTION</b> HEPSERA (adefovir dipivoxil) lamivudine hbv <b>TABLET</b> VEMLIDY (tenofovir alafenamide fumarate)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HEPATITIS C TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>DIRECT ACTING ANTI-VIRAL</b>		<a href="#">Hepatitis C Treatments PA Form</a> <a href="#">Hepatitis C Criteria</a> <ul style="list-style-type: none"> <li>▪ Non-preferred products require trial of preferred agents within the same group and/or will only be considered with documentation of why the preferred product within this drug class is not appropriate for patient</li> <li>▪ Patients newly eligible for Medicaid will be allowed to complete treatment with the original that treatment was initially authorized by another payor</li> </ul> <p>Drug-specific criteria: Trial with with a preferred agent not required in the following:</p> <ul style="list-style-type: none"> <li>▪ <b>Harvoni:</b> <ul style="list-style-type: none"> <li>○ Post liver transplant for genotype 1 or 4</li> </ul> </li> <li>▪ <b>Vosevi:</b> Requires documentation of non-response after previous treatment course of Direct Acting Anti-viral agent (DAA) for genotype 1-6 without cirrhosis or with compensated cirrhosis</li> </ul>
sofosbuvir/velpatasvir (generic Epclusa) <sup>CL</sup> MAVYRET (glecaprevir/pibrentasvir) <b>TABLET</b> <sup>CL</sup> , <b>PELLET</b> <sup>AL,CL,NR</sup> VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) <sup>CL</sup>	HARVONI 200/45MG, <b>TABLET</b> (sofosbuvir/ledipasvir) <sup>CL</sup> HARVONI (ledipasvir/sofosbuvir) <sup>CL</sup> <b>PELLET</b> sofosbuvir/ledipasvir (generic Harvoni) <sup>CL</sup> SOVALDI (sofosbuvir) <sup>CL</sup> <b>PELLET</b> SOVALDI <b>TABLET</b> (sofosbuvir) <sup>CL</sup> VIEKIRA <b>PAK</b> (ombitasvir/paritaprevir/ritonavir/dasabuvir) <sup>CL</sup> ZEPATIER (elbasvir/grazoprevir) <sup>CL</sup>	
<b>RIBAVIRIN</b>		
ribavirin 200mg <b>CAPSULE, TABLET</b>	REBETOL (ribavirin)	
<b>INTERFERON</b>		
PEGASYS (pegylated interferon alfa-2a) <sup>CL</sup> PEG-INTRON (pegylated interferon alfa-2b) <sup>CL</sup>		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HISTAMINE II RECEPTOR BLOCKERS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
famotidine <b>TABLET</b> (generic for Pepcid) nizatidine <b>SOLUTION</b> (generic for Axid)	cimetidine <b>TABLET, SOLUTION</b> <sup>CL</sup> (generic for Tagamet) famotidine <b>SUSPENSION</b> nizatidine <b>CAP</b> (generic for Axid) ranitidine <b>CAPSULE</b> , (generic for Zantac) ranitidine OTC, SYRUP, TABLET (generic for Zantac)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Cimetidine:</b> Approved for viral <i>M. contagiosum</i> or common wart <i>V. Vulgaris</i> treatment</li> <li><b>cimetidine solution/ famotidine suspension/ranitidine syrup:</b> Requires clinical reason why nizatidine syrup cannot be used <b>***famotidine suspension is authorized during shortage of nizatidine syrup.***</b></li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HIV / AIDS<sup>CL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CCR5 ANTAGONISTS</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have a diagnosis of HIV/AIDS and patient specific documentation of why the preferred products within this drug class are not appropriate for patient, including, but not limited to, drug resistance or concomitant conditions not recommended with preferred agents</li> <li>▪ Patients undergoing treatment at the time of any preferred status change will be allowed to continue therapy</li> <li>▪ Diagnosis of HIV/AIDS required</li> </ul> <p style="text-align: center;">OR</p> <ul style="list-style-type: none"> <li>▪ Pre and Post Exposure Prophylaxis</li> </ul>
SELZENTRY <b>SOLN, TAB</b> (maraviroc)		
<b>FUSION INHIBITORS</b>		
FUZEON <b>SUB-Q</b> (enfuvirtide) <sup>QL</sup>		
<b>HIV-1 ATTACHMENT INHIBITOR</b>		
	RUKOBIA ER (fostemsavir) <sup>AL, QL</sup>	
<b>INTEGRASE STRAND TRANSFER INHIBITORS (INSTIs)</b>		
ISENTRESS (raltegravir) <sup>QL</sup> ISENTRESS HD (raltegravir) TIVICAY (dolutegravir)	TIVICAY PD (dolutegravir) VOCABRIA (cabotegravir) <sup>NR</sup>	
<b>NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)</b>		
efavirenz <b>CAPSULE, TABLET</b> (generic Sustiva) INTELENCE (etravirine) <sup>QL</sup> PIFELTRO (doravirine) <sup>QL</sup>	EDURANT (rilpivirine) ETRAVIRINE (new generic for Intelence) <sup>NR, QL</sup> nevirapine IR, ER (generic Viramune/Viramune XR) RESCRIPTOR (delavirdine) SUSTIVA <b>CAPSULE, TABLET</b> (efavirenz) VIRAMUNE (nevirapine) <b>SUSP</b>	
<b>NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)</b>		
abacavir <b>SOLN, TABLET</b> (generic Ziagen) EMTRIVA <b>CAPSULE, SOLN</b> (emtricitabine) lamivudine <b>SOLN, TABLET</b> (generic Epivir) zidovudine <b>CAPSULE, SYRUP, TABLET</b> (generic Retrovir)	didanosine DR (generic Videx EC) emtricitabine <b>CAPSULE</b> (generic for Emtriva) EPIVIR (lamivudine) RETROVIR (zidovudine) stavudine <b>CAPSULE</b> (generic Zerit) VIDEX (didanosine) <b>SOLN</b> ZIAGEN (abacavir)	
<b>NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)</b>		
tenofovir <b>TABLET</b> (generic Viread)	VIREAD (tenofovir) <b>POWDER</b>	
<b>PHARMACOKINETIC ENHANCER</b>		
	TYBOST (cobicistat) <sup>QL</sup>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HIV / AIDS<sup>CL</sup> (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>PROTEASE INHIBITORS</b>		
atazanavir <b>CAPSULE</b> (generic Reyataz) LEXIVA <b>SUSP</b> (fosamprenavir) ritonavir <b>TABLET</b> (generic Norvir)	APTIVUS <b>CAPSULE, SOLN</b> (tipranavir) CRIXIVAN (indinavir) fosamprenavir <b>TAB</b> (generic Lexiva) INVIRASE (saquinavir) LEXIVA <b>TABLET</b> (fosamprenavir) NORVIR <b>POWDER, SOLN</b> (ritonavir) NORVIR (ritonavir) <b>TAB</b> PREZISTA (darunavir) <b>SUSP, TABLET</b> REYATAZ <b>POWDER</b> (atazanavir) VIRACEPT (nelfinavir)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have a diagnosis of HIV/AIDS and patient specific documentation of why the preferred products within this drug class are not appropriate for patient, including, but not limited to, drug resistance or concomitant conditions not recommended with preferred agents</li> <li>▪ Patients undergoing treatment at the time of any preferred status change will be allowed to continue therapy</li> <li>▪ Diagnosis of HIV/AIDS required</li> </ul> OR <ul style="list-style-type: none"> <li>▪ Pre and Post Exposure Prophylaxis</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HIV / AIDS<sup>CL</sup> (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>COMBINATION PROTEASE INHIBITORS (PIs) or PIs plus PHARMACOKINETIC ENHANCER</b>		
EVOTAZ (atazanavir/cobicistat) <sup>QL</sup> lopinavir/ritonavir <b>SOLN</b> (generic Kaletra)	KALETRA <b>SOLN</b> (lopinavir/ritonavir) KALETRA <b>TAB</b> (lopinavir/ritonavir) lopinavir/ritonavir <b>TAB</b> (generic Kaletra) <sup>NR</sup> PREZCOBIX (darunavir/cobicistat) <sup>QL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have a diagnosis of HIV/AIDS and patient specific documentation of why the preferred products within this drug class are not appropriate for patient, including, but not limited to, drug resistance or concomitant conditions not recommended with preferred agents</li> <li>▪ Patients undergoing treatment at the time of any preferred status change will be allowed to continue therapy</li> <li>▪ Diagnosis of HIV/AIDS required</li> </ul> <p>OR</p> <ul style="list-style-type: none"> <li>▪ Pre and Post Exposure Prophylaxis</li> </ul>
<b>COMBINATION NUCLEOS(T)IDE REVERSE TRANSCRIPTASE INHIBITORS</b>		
abacavir/lamivudine (generic Epzicom) CIMDUO (lamivudine/tenofovir) <sup>QL</sup> DESCOVY (emtricitabine/tenofovir) <sup>QL, CL</sup> lamivudine/zidovudine (generic Combivir) TRUVADA (emtricitabine/tenofovir)	abacavir/lamivudine/zidovudine (generic Trizivir) COMBIVIR (lamivudine/zidovudine) <i>emtricitabine/tenofovir (generic Truvada)<sup>CL</sup></i> EPZICOM (abacavir sulfate/lamivudine) TEMIXYS (lamivudine/tenofovir) <sup>QL</sup> TRIZIVIR (abacavir/lamivudine/zidovudine)	<p>Drug-Specific Criteria</p> <p><b>Descovy:</b></p> <ul style="list-style-type: none"> <li>• <i>Approval will be granted for a diagnosis of HIV/AIDS</i></li> </ul> <p><i>For PrEP use: Will require prior approval with a documentation of a contraindication to Truvada.</i></p>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HIV / AIDS<sup>CL</sup> (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>COMBINATION PRODUCTS – MULTIPLE CLASSES</b>		
ATRIPLA (tenofovir/emtricitabine/efavirenz) BIKTARVY (bictegravir/emtricitabine/tenofovir) <sup>QL</sup> COMPLERA (rilpivirine/emtricitabine/tenofovir) DELSTRIGO (doravirine/lamivudine/tenofovir) <sup>QL</sup> GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir) <sup>QL, AL</sup> ODEFSEY (emtricitabine/rilpivirine/tenofovir) <sup>QL</sup> STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) <sup>QL</sup> SYMFI (efavirenz/lamivudine/tenofovir) <sup>QL</sup> SYMFI LO (efavirenz/lamivudine/tenofovir) <sup>QL</sup> TRIUMEQ (dolutegravir/abacavir/lamivudine)	DOVATO (dolutegravir/lamivudine) <sup>QL</sup> <i>efavirenz/emtricitabine/tenofovir (generic Atripla)<sup>CL</sup></i> <i>efavirenz/lamivudine/tenofovir (generic for Symfi)<sup>QL</sup></i> <i>efavirenz/lamivudine/tenofovir (generic for Symfi Lo)<sup>QL</sup></i> JULUCA (dolutegravir/rilpivirine) <sup>QL</sup> SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir) <sup>QL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have a diagnosis of HIV/AIDS and patient specific documentation of why the preferred products within this drug class are not appropriate for patient, including, but not limited to, drug resistance or concomitant conditions not recommended with preferred agents</li> <li>▪ Patients undergoing treatment at the time of any preferred status change will be allowed to continue therapy</li> <li>▪ Diagnosis of HIV/AIDS required</li> </ul> <p style="text-align: center;">OR</p> <ul style="list-style-type: none"> <li>▪ Pre and Post Exposure Prophylaxis</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
acarbose (generic for Precose)	miglitol (generic for Glyset) GLYSET (miglitol)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA)<sup>CL</sup></b>		Preferred agents require metformin trial and diagnosis of diabetes
BYDUREON (exenatide ER) BYDUREON <b>PEN</b> (exenatide ER) subcutaneous BYETTA (exenatide) subcutaneous TRULICITY (dulaglutide) VICTOZA (liraglutide) subcutaneous	ADLYXIN (lixisenatide) BYDUREON BCISE <b>PEN</b> (exenatide) <sup>QL</sup> OZEMPIC (semaglutide) RYBELSUS (semaglutide) TANZEUM (albiglutide)	
<b>INSULIN/GLP-1 RA COMBINATIONS</b>		Non-preferred agents will be approved for patients who have: <ul style="list-style-type: none"> <li>▪ Failed a trial of TWO preferred agents within GLP-1 RA</li> </ul> <b>AND</b> <ul style="list-style-type: none"> <li>▪ Diagnosis of diabetes with HbA1C ≥ 7 <b>AND</b></li> <li>▪ Trial of metformin, or contraindication or intolerance to metformin</li> </ul>
	SOLIQUA (insulin glargine/lixisenatide) XULTOPHY (insulin degludec/liraglutide)	
<b>AMYLIN ANALOG</b>		ALL criteria must be met <ul style="list-style-type: none"> <li>▪ Concurrent use of short-acting mealtime insulin</li> <li>▪ Current therapy compliance</li> <li>▪ No diagnosis of gastroparesis</li> <li>▪ HbA1C ≤ 9% within last 90 days</li> <li>▪ Fingerstick monitoring of glucose during <u>initiation</u> of therapy</li> </ul>
	SYMLIN (pramlintide) subcutaneous	
<b>DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR<sup>QL</sup></b>		Non-preferred DPP-4s will be approved for patients who have failed a trial of ONE preferred agent within DPP-4
GLYXAMBI (empagliflozin/linagliptin) JANUMET (sitagliptin/metformin) JANUMET XR (sitagliptin/metformin) JANUVIA (sitagliptin) JENTADUETO (linagliptin/metformin) TRADJENTA (linagliptin)	alogliptin (generic for Nesina) alogliptin/metformin (generic for Kazano) JENTADUETO XR (linagliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin) ONGLYZA (saxagliptin) alogliptin/pioglitazone (generic for Oseni) QTERN (dapagliflozin/saxagliptin) STEGLUJAN (ertugliflozin/sitagliptin) TRIJARDY XR (empagliflozin/linagliptin/metformin) <sup>AL</sup>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## HYPOGLYCEMICS, INSULIN AND RELATED DRUGS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
HUMALOG (insulin lispro) U-100 <b>CARTRIDGE, PEN, VIAL</b> HUMALOG JR. (insulin lispro) U-100 <b>KWIKPEN</b> HUMALOG MIX <b>VIAL</b> (insulin lispro/lispro protamine) HUMALOG MIX <b>KWIKPEN</b> (insulin lispro/lispro protamine) HUMULIN (insulin) <b>VIAL</b> HUMULIN 70/30 <b>VIAL</b> HUMULIN U-500 <b>VIAL</b> HUMULIN R U-500 <b>KWIKPEN<sup>CL</sup></b> HUMULIN OTC <b>PEN</b> HUMULIN 70/30 OTC <b>PEN</b> insulin aspart (generic for Novolog) insulin aspart/insulin aspart protamine <b>PEN, VIAL</b> (generic for Novolog Mix) insulin lispro (generic for Humalog) <b>PEN, VIAL, JR KWIKPEN</b> insulin lispro/lispro protamine <b>KWIKPEN</b> (Humalog Mix Kwikpen) LANTUS SOLOSTAR <b>PEN</b> (insulin glargine) LANTUS (insulin glargine) <b>VIAL</b> LEVEMIR (insulin detemir) <b>PEN, VIAL</b> NOVOLOG (insulin aspart) <b>CARTRIDGE, FLEXPEN, VIAL</b> NOVOLOG MIX <b>FLEXPEN, VIAL</b> (insulin aspart/aspart protamine)	ADMELOG (insulin lispro) <b>PEN, VIAL</b> AFREZZA (regular insulin) <b>INHALATION</b> APIDRA (insulin glulisine) BASAGLAR (insulin glargine, rec) <b>PEN</b> FIASP (insulin aspart) <b>CARTRIDGE, PEN, VIAL</b> HUMALOG (insulin lispro) U-200 <b>KWIKPEN</b> insulin Glargine-YFGN <b>PEN, VIAL</b> (generic for Semglee-YFGN) <sup>NR</sup> LYUMJEV <b>KWIKPEN, VIAL</b> (insulin lispro-aabc) NOVOLIN (insulin) NOVOLIN 70/30 <b>VIAL</b> (insulin) TOUJEO SOLOSTAR (insulin glargine) SEMGLEE (insulin glargine) <b>PEN, VIAL</b> SEMGLEE YFGN (insulin glargine) <b>PEN, VIAL<sup>NR</sup></b> TRESIBA (insulin degludec)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Afrezza<sup>®</sup></b>: Approved for T1DM on long-acting insulin with no current history of smoking or chronic lung disease</li> <li><b>Humulin<sup>®</sup> R U-500 Kwikpen</b>: Approved for physical reasons – such as dexterity problems and vision impairment                             <ul style="list-style-type: none"> <li>Usage must be for self-administration, not only convenience</li> <li>Patient requires &gt;200 units/day</li> <li>Safety reason patient can't use vial/syringe</li> </ul> </li> </ul>

## HYPOGLYCEMICS, MEGLITINIDES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
repaglinide (generic for Prandin)	nateglinide (generic for Starlix) <sup>CL</sup> repaglinide/metformin (generic for Prandimet) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients with: Failure of a trial of ONE preferred agent in another Hypoglycemic class OR T2DM and inadequate glycemic control</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HYPOGLYCEMICS, METFORMINS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
metformin IR & ER (generic Glucophage/Glucophage XR)	metformin ER (generic Fortamet/Glumetza) metformin <b>SOLUTION</b> (generic Riomet) RIOMET ER (metformin ER) <sup>AL</sup>	<ul style="list-style-type: none"> <li>• <b>Metformin ER (generic Fortamet®/Glumetza®):</b> Requires clinical reason why generic Glucophage XR® cannot be used</li> <li>• <b>Metformin solution:</b> Prior authorization not required for age &lt;7 years</li> </ul>

## HYPOGLYCEMICS, SGLT2

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
FARXIGA (dapagliflozin) <sup>QL,CL</sup> INVOKAMET (canagliflozin/metformin) <sup>QL,CL</sup> INVOKANA (canagliflozin) <sup>CL</sup> JARDIANCE (empagliflozin) <sup>QL,CL</sup> SYNJARDY (empagliflozin/metformin) <sup>AL,CL,QL</sup> XIGDUO XR (dapagliflozin/metformin) <sup>QL,CL</sup>	INVOKAMET XR (canagliflozin/metformin) <sup>QL</sup> SEGLUOMET (ertugliflozin/metformin) <sup>QL</sup> STEGLATRO (ertugliflozin) <sup>QL</sup> SYNJARDY XR (empagliflozin/ metformin) <sup>AL,QL</sup>	<ul style="list-style-type: none"> <li>• Preferred agents are Approved for diagnosis of diabetes AND a trial of metformin</li> <li>• Non-preferred agents will be approved for patients who have failed a trial with ONE preferred agent within this drug class</li> </ul> <p style="color: red;"><b>Drug Specific Criteria:</b> <b>Farxiga and Jardiance:</b></p> <ul style="list-style-type: none"> <li>- Approved for a diagnosis of heart failure with reduced ejection fraction (NYHA class II-IV)</li> </ul>

## HYPOGLYCEMICS, SULFONYLUREAS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
glimepiride (generic Amaryl) glipizide IR & ER (generic Glucotrol/ Glucotrol XL) glyburide (generic Diabeta/Glynase)	chlorpropamide tolazamide tolbutamide	<ul style="list-style-type: none"> <li>• Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>
SULFONYLUREA COMBINATIONS		
glipizide/metformin glyburide/metformin (generic Glucovance)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## HYPOGLYCEMICS, TZD

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>THIAOLIDINEDIONES (TZDs)</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of THE preferred agent within this drug class</li> </ul>
pioglitazone (generic for Actos)	AVANDIA (rosiglitazone)	
<b>TZD COMBINATIONS</b>		<ul style="list-style-type: none"> <li>▪ <b>Combination products:</b> Require clinical reason why individual ingredients cannot be used</li> </ul>
	pioglitazone/glimepiride (generic for Duetact) pioglitazone/metformin (generic for Actoplus Met)	

## IDIOPATHIC PULMONARY FIBROSIS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
OFEV (nintedanib esylate) <sup>CL</sup>	ESBRIET (pirfenidone)	<ul style="list-style-type: none"> <li>• Non-preferred agent requires trial of preferred agent within this drug class</li> <li>• FDA approved indication required – ICD-10 diagnosis code</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## IMMUNOMODULATORS, ASTHMA<sup>CL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<p><i>FASENRA (benralizumab)<sup>AL</sup> <b>PEN</b></i>  <i><b>XOLAIR (omalizumab) SYR<sup>AL, QL</sup></b></i></p>	<p><i>NUCALA (mepolizumab)<sup>AL</sup></i>  <b>AUTO-INJ, SYR,</b></p>	<p><u><a href="#">Asthma Immunomodulator PA Form</a></u></p> <ul style="list-style-type: none"> <li>Non-preferred agents require a trial of a preferred agent within this drug class with the same indication</li> </ul> <p>Drug Specific Criteria:</p> <p><b>Dupixent:</b> is indicated for</p> <ul style="list-style-type: none"> <li>Patients 6 years and older as an add-on maintenance treatment in patients with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma</li> <li>For other indications, see Immunomodulators, Atopic Dermatitis</li> </ul> <p><b>Fasenra:</b> is indicated for</p> <ul style="list-style-type: none"> <li>Patient 12 years and older for add on maintenance treatment of severe asthma, and with an eosinophilic phenotype</li> </ul> <p><b>Nucala:</b> is indicated for</p> <ul style="list-style-type: none"> <li>Patients 6 years and older for add on maintenance treatment of severe asthma, and with an eosinophilic phenotype</li> <li>Patients 12 years and older with hypereosinophilic syndrome (HES) for <math>\geq 6</math> months without identifiable non-hematologic secondary cause</li> <li>Patients 18 years and older for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRWSwNP) with inadequate response to nasal corticosteroids.</li> <li>Adult patients with eosinophilic granulomatosis with polyangiitis</li> </ul> <p><b>Xolair Syringe-</b> is indicated for</p> <ul style="list-style-type: none"> <li>Patients 6 years and older for moderate to severe persistent asthma with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids</li> <li>Patients 12 years and older with Chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment</li> <li>Patients 18 years and older with Nasal Polyps with inadequate response to nasal corticosteroids. As add-on maintenance treatment</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## IMMUNOMODULATORS, ATOPIC DERMATITIS<sup>AL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ELIDEL (pimecrolimus) EUCRISA (crisaborole) <sup>CL,QL</sup>	DUPIXENT (dupilumab) <sup>AL,CL</sup> DUPIXENT <b>PEN</b> <sup>AL</sup> Opzelura (ruxolitinib phosphate) <b>CREAM</b> <sup>AL,NR,QL</sup> pimecrolimus (generic for Elidel) tacrolimus (generic for Protopic) <sup>CL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents require: Trial of a topical steroid AND Trial of one preferred product within this drug class</li> </ul> Drug-specific criteria: <b>Dupixent:</b> Indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. -as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. - as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) <ul style="list-style-type: none"> <li>• <b>Eucrisa:</b> Requires use and failure of 1 topical steroid or Elidel.</li> </ul>

## IMMUNOMODULATORS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
imiquimod (generic for Aldara)	ALDARA (imiquimod) imiquimod (generic for Zyclara) podofilox (generic for Condyllox) VEREGEN (sinecatechins) ZYCLARA (imiquimod)	<ul style="list-style-type: none"> <li>• Non-preferred agents require clinical reason why preferred agent within this drug class cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## IMMUNOSUPPRESSIVES, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
azathioprine (generic Imuran) cyclosporine, modified <b>CAPSULE</b> (generic Neoral) mycophenolate <b>CAPSULE, TABLET</b> (generic Cellcept) RAPAMUNE (sirolimus) <b>SOLUTION</b> RAPAMUNE (sirolimus) <b>TABLET</b> tacrolimus ZORTRESS (everolimus) <sup>AL</sup>	ASTAGRAF XL (tacrolimus) AZASAN (azathioprine) azathioprine (generic Azasan, Imuran 75 mg and 100 mg) <sup>NR</sup> cyclosporine <b>CAPSULE, SOFTGEL</b> cyclosporine, modified <b>SOLUTION</b> (generic Neoral) ENVARSUS XR (tacrolimus) GENGRAF (cyclosporine, modified) <b>CAPSULE, SOLUTION</b> mycophenolate <b>SUSPENSION</b> (generic Cellcept) mycophenolic acid MYFORTIC (mycophenolate sodium) PROGRAF (tacrolimus) <b>CAPSULE,</b> <b>PACKET</b> SANDIMMUNE (cyclosporine) <b>CAPSULE, SOLUTION</b> sirolimus <b>SOLUTION, TABLET</b> (generic Rapamune) everolimus (generic for Zortress) <sup>AL</sup>	Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class  ▪ Patients established on existing therapy will be allowed to continue

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## INTRANASAL RHINITIS DRUGS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ANTICHOLINERGICS</b>		Non-preferred agents will be approved for patients who have failed a 30-day trial of ONE preferred agent within this drug class
ipratropium (generic for Atrovent)		
<b>ANTI-HISTAMINES</b>		Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>mometasone:</b> Prior authorization NOT required for children ≤ 12 years</li> <li>▪ <b>budesonide:</b> Approved for use in Pregnancy (Pregnancy Category B)</li> <li>▪ <b>Veramyst®:</b> Prior authorization NOT required for children ≤ 12 years</li> <li>▪ <b>Xhance:</b> Indicated for treatment of nasal polyps in ≥ 18 years only</li> </ul>
azelastine 0.1% (generic for Astelin)	azelastine 0.15% (generic for Astepro) <i>azelastine/fluticasone (generic for Dymista)</i> olopatadine (generic for Patanase)	
<b>CORTICOSTEROIDS</b>		
fluticasone (generic for Flonase)	BECONASE AQ (beclomethasone) budesonide Rx (generic for Rhinocort) flunisolide (generic for Nasalide) mometasone (generic for Nasonex) OMNARIS (ciclesonide) QNASL 40 & 80 (beclomethasone) TICANASE (fluticasone) VERAMYST (fluticasone) XHANCE (fluticasone) ZETONNA (ciclesonide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## LEUKOTRIENE MODIFIERS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
montelukast <b>TABLET/CHEWABLE</b> (generic for Singulair) <sup>AL</sup>	montelukast <b>GRANULES</b> (generic for Singulair) <sup>CL, AL</sup> zafirlukast (generic for Accolate) zileuton ER (generic for Zyflo CR) ZYFLO (zileuton)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 30-day trial of THE preferred agent within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>montelukast granules:</b> PA not required for age &lt; 2 years</li> </ul>

## LINCOSAMIDES / OXAZOLIDINONES / STREPTOGRAMINS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
clindamycin <b>CAPSULE</b> clindamycin palmitate <b>SOLUTION</b> linezolid <b>TABLET</b>	CLEOCIN (clindamycin ) <b>CAPSULE</b> CLEOCIN PALMITATE (clindamycin) linezolid <b>SUSPENSION</b> SIVEXTRO (tedizolid phosphate) ZYVOX (linezolid) <b>SUSPENSION, TABLET</b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## LIPOTROPICS, OTHER

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BILE ACID SEQUESTRANTS</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> <li>Drug-specific criteria:               <ul style="list-style-type: none"> <li>▪ <b>Colesevelam</b>: Trial not required for diabetes control and monotherapy with metformin, sulfonylurea, or insulin has been inadequate</li> <li>▪ <b>Juxtapid®/ Kynamro®</b>:                   <ul style="list-style-type: none"> <li>○ Approved for diagnosis of homozygous familial hypercholesterolemia (HoFH) OR</li> <li>○ Treatment failure/maximized dosing/contraindication to ALL the following: statins, ezetimibe, niacin, fibric acid derivatives, omega-3 agents, bile acid sequestrants</li> <li>○ Require faxed copy of REMS PA form</li> </ul> </li> <li>▪ <b>Vascepa®</b>: Approved for TG ≥ 500</li> </ul> </li> </ul>
cholestyramine (generic Questran) colestipol <b>TABLETS</b> (generic Colestid)	colesevelam (generic Welchol) <b>TABLET, PACKET</b> colestipol <b>GRANULES</b> (generic Colestid) QUESTRAN LIGHT (cholestyramine)	
<b>TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>		
	JUXTAPID (lomitapide) <sup>CL</sup> KYNAMRO (mipomersen) <sup>CL</sup>	
<b>FIBRIC ACID DERIVATIVES</b>		
fenofibrate (generic Tricor) fenofibrate (generic Lofibra) gemfibrozil (generic Lopid)	fenofibric acid (generic Fibricor/Trilipix) fenofibrate (generic Antara/Fenoglide/ Lipofen/Triglide)	
<b>NIACIN</b>		
niacin ER (generic for Niaspan)	NIACOR (niacin IR) NIASPAN (niacin ER)	
<b>OMEGA-3 FATTY ACIDS</b>		
omega-3 fatty acids (generic for Lovaza)	icosapent (generic for Vascepa) <sup>CL</sup> omega-3 OTC VASCEPA (icosapent) <sup>CL</sup>	
<b>CHOLESTEROL ABSORPTION INHIBITORS</b>		
ezetimibe (generic for Zetia)	<i>NEXLIZET (bempedoic acid/ ezetimibe)</i> <sup>QL</sup>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## LIPOTROPICS, OTHER (continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS</b>		
	PRALUENT (alorocumab) <sup>CL</sup> REPATHA (evolocumab) <sup>CL</sup>	<ul style="list-style-type: none"> <li>▪ <b>Praluent®:</b> Approved for diagnoses of:               <ul style="list-style-type: none"> <li>• atherosclerotic cardiovascular disease (ASCVD)</li> <li>• heterozygous familial hypercholesterolemia (HeFH)</li> <li>• Homozygous familial hypercholesterolemia (HoFH) as an adjunct to other LDL-C lowering therapies</li> <li>•</li> </ul> </li> <li>AND               <ul style="list-style-type: none"> <li>• Maximized high-intensity statin WITH ezetimibe for at 3 continuous months</li> <li>• Failure to reach target LDL-C levels: ASCVD - &lt; 70 mg/dL, HeFH - &lt; 100 mg/dL</li> </ul> </li> <li>▪ <b>Repatha®:</b> Approved for:               <ul style="list-style-type: none"> <li>• adult diagnoses of atherosclerotic cardiovascular disease (ASCVD)</li> <li>• heterozygous familial hypercholesterolemia (HeFH)</li> <li>• homozygous familial hypercholesterolemia (HoFH) in age ≥ 13</li> <li>• statin-induce rhabdomyolysis</li> </ul> </li> <li>AND               <ul style="list-style-type: none"> <li>• Maximized high-intensity statin WITH ezetimibe for 3+ continuous months</li> <li>• Failure to reach target LDL-C levels: ASCVD - &lt; 70 mg/dL, HeFH - &lt; 100 mg/dL</li> <li>• Concurrent use of maximally-tolerated statin must continue, except for statin-induced rhabdomyolysis or a contraindication to a statin</li> </ul> </li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## LIPOTROPICS, STATINS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>STATINS</b>		
atorvastatin (generic Lipitor) <sup>QL</sup> lovastatin (generic Mevacor) pravastatin (generic Pravachol) rosuvastatin (generic Crestor) simvastatin (generic Zocor)	ALTOPREV (lovastatin ER) <sup>CL</sup> EZALLOR SPRINKLE (rosuvastatin) <sup>QL</sup> fluvastatin IR/ER (generic Lescol/ Lescol XL) LIVALO (pitavastatin) ZYPITAMAG (pitavastatin)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agent within this drug class, within the last 12 months</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Altoprev®</b>: One of the TWO trials must be IR lovastatin</li> <li>▪ <b>Combination products</b>: Require clinical reason why individual ingredients cannot be used</li> <li>▪ <b>fluvastatin ER</b>: Requires trial of TWO preferred agents AND trial of IR fluvastatin OR clinical reason IR cannot be used</li> <li>▪ <b>simvastatin/ezetimibe</b>: Approved for 3-month continuous trial of ONE standard dose statin</li> </ul>
<b>STATIN COMBINATIONS</b>		
	atorvastatin/amlodipine (generic Caduet) simvastatin/ezetimibe (generic Vytorin)	

## MACROLIDES AND KETOLIDES, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>MACROLIDES</b>		
azithromycin (generic Zithromax) clarithromycin <b>TABLET, SUSPENSION</b> (generic Biaxin) erythromycin ethylsuccinate <b>SUSPENSION</b>	clarithromycin ER (generic Biaxin XL) E.E.S. <b>SUSPENSION (erythromycin ethylsuccinate)</b> E.E.S. <b>TABLET</b> (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYPED <b>SUSPENSION</b> (erythromycin) ERYTHROCIN (erythromycin) erythromycin base <b>TABLET, CAPSULE</b>	<ul style="list-style-type: none"> <li>• Require clinical reason why preferred products within this drug class cannot be used AND ≥ 3-day trial on a preferred product</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## METHOTREXATE

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
methotrexate <b>PF VIAL, TABLET, VIAL</b>	OTREXUP (methotrexate) <b>SUB-Q</b> RASUVO (methotrexate) <b>SUB-Q</b> <b>REDITREX</b> (methotrexate) <b>SUB-Q AL</b> TREXALL (methotrexate) <b>TABLET</b> XATMEP (methotrexate) <b>SOLUTION</b>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for FDA-approved indications</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Xatmep™</b>: Indicated for pediatric patients only</li> </ul>

## MOVEMENT DISORDERS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
AUSTEDO (deutetrabenazine) <sup>CL</sup> <b>INGREZZA (valbenazine)<sup>AL,CL,QL</sup></b> <b>CAP</b> tetrabenazine (generic for Xenazine) <sup>CL</sup>	INGREZZA (valbenazine) <sup>CL</sup> <b>INITIATION PACK</b> XENAZINE (tetrabenazine) <sup>CL</sup>	<p>Non-preferred agent requires trial of Austedo</p> <p>All drugs require an FDA approved indication – ICD-10 diagnosis code required.</p> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Austedo</b>: Diagnosis of Tardive Dyskinesia or chorea associated with Huntington's Disease; Requires a Step through tetrabenazine with the diagnosis of chorea associated with Huntington's Disease</li> <li><b>Ingrezza</b>: Diagnosis of Tardive Dyskinesia in adults and trial of Austedo</li> <li><b>tetrabenazine</b>: Diagnosis of chorea with Huntington's Disease</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## MULTIPLE SCLEROSIS DRUGS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
AVONEX (interferon beta-1a) <sup>QL</sup> BETASERON (interferon beta-1b) <sup>QL</sup> COPAXONE 20mg (glatiramer) <sup>QL</sup> KESIMPTA ( <i>Ofatumumab</i> ) <sup>CL, QL</sup> TECFIDERA (dimethyl fumarate)	AUBAGIO (teriflunomide) BAFIERTAM ( <i>monomethyl fumarate</i> ) <sup>QL</sup> dalfampridine (generic Ampyra) <sup>QL</sup> dimethyl fumarate ( <i>generic for Tecfidera</i> ) EXTAVIA (interferon beta-1b) <sup>QL</sup> GILENYA (fingolimod) <sup>QL</sup> glatiramer (generic Copaxone) <sup>QL</sup> MAVENCLAD (cladribine) MAYZENT (siponimod) <sup>QL</sup> PLEGRIDY (peginterferon beta-1a) <sup>QL</sup> PONVORY (ponesimod) <sup>NR</sup> REBIF (interferon beta-1a) <sup>QL</sup> VUMERITY (diroximel) <sup>QL</sup> ZEPOSIA ( <i>ozanimod</i> ) <sup>AL, QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of <b>ONE</b> preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Ampyra</b><sup>®</sup>: Approved for diagnosis of gait disorder associated with MS AND EDSS score ≤ 7</li> <li><b>Plegridy</b>: Approved for diagnosis of relapsing MS</li> <li><b>Kesimpta</b>: Approved for patients who have failed a trial of a preferred injectable agent within this class</li> </ul>

## NITROFURAN DERIVATIVES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
nitrofurantoin macrocrystals <b>CAPSULE</b> (generic for Macrochantin) nitrofurantoin monohydrate-macrocrystals <b>CAPSULE</b> (generic for Macrobid)	nitrofurantoin <b>SUSPENSION</b> (generic for Furadantin)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of <b>ONE</b> preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## NSAIDs, ORAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>COX-I SELECTIVE</b>		<ul style="list-style-type: none"> <li>• Non-preferred agents within COX-1 SELECTIVE group will be approved for patients who have failed no less than 30-day trial of TWO preferred agents within this drug class</li> <li>Drug-specific criteria:               <ul style="list-style-type: none"> <li>▪ <b>Arthrotec®</b>: Requires clinical reason why individual ingredients cannot be used</li> <li>▪ <b>Duexis®/Vimovo®</b>: Requires clinical reason why individual agents cannot be used</li> <li>▪ <b>meclofenamate</b>: Approvable without trial of preferred agents for menorrhagia</li> </ul> </li> </ul>
diclofenac sodium (generic for Voltaren)	diclofenac potassium (generic for Cataflam, Zipsor)	
ibuprofen OTC, Rx (generic for Advil, Motrin) <b>CHEW, DROPS, SUSPENSION, TABLET</b>	diclofenac SR (generic for Voltaren-XR)	
indomethacin <b>CAPSULE</b> (generic for Indocin)	diflunisal (generic for Dolobid)	
ketorolac (generic for Toradol)	etodolac & SR (generic for Lodine/XL)	
meloxicam <b>TABLET</b> (generic for Mobic)	fenoprofen (generic for Nalfon)	
nabumetone (generic for Relafen)	flurbiprofen (generic for Ansaid)	
naproxen Rx, OTC (generic for Naprosyn)	ibuprofen OTC (generic for Advil, Motrin) <b>CAPSULE</b>	
naproxen enteric coated	indomethacin ER (generic for Indocin)	
sulindac (generic for Clinoril)	<b>INDOCIN RECTAL, SUSPENSION</b>	
	ketoprofen & ER (generic for Orudis)	
	meclofenamate (generic for Meclomen)	
	mefenamic acid (generic for Ponstel)	
	<b>meloxicam CAP</b> (generic Vivlodex) <sup>CL, QL</sup>	
	naproxen CR (generic for Naprelan)	
	naproxen <b>SUSPENSION</b> (generic for Naprosyn)	
	naproxen sodium (generic for Anaprox)	
	<i>naproxen-esomeprazole (generic for Vimovo)</i>	
	oxaprozin (generic for Daypro)	
	piroxicam (generic for Feldene)	
	RELAFEN DS (nabumetone)	
	tolmetin (generic for Tolectin)	
	Ketorolac Nasal <sup>QL</sup> (generic for Sprix)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## NSAIDs, ORAL (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>COX-I SELECTIVE (continued)</b>		
	<b>ALL BRAND NAME NSAIDs including:</b> CAMBIA (diclofenac oral solution) DUEXIS (ibuprofen/famotidine) <sup>CL</sup> <b>ibuprofen/famotidine (generic Duexis)<sup>CL</sup></b> SPRIX (ketorolac nasal spray) <b>NASAL<sup>QL, CL</sup></b> TIVORBEX (indomethacin) VIVLODEX (meloxicam submicronized) ZIPSOR (diclofenac) ZORVOLEX (diclofenac)	Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Sprix<sup>®</sup></b>: Approved for patients unable to tolerate, swallow OR absorb oral NSAIDs OR contraindication OR trial of TWO preferred oral NSAIDs</li> <li>▪ <b>Tivorbex<sup>®</sup></b>: Requires clinical reason why indomethacin capsules cannot be used</li> <li>▪ <b>Zorvolex<sup>®</sup></b>: Requires trial of oral diclofenac OR clinical reason why diclofenac potassium/sodium cannot be used</li> <li>•</li> </ul>
<b>NSAID/GI PROTECTANT COMBINATIONS</b>		
	diclofenac/misoprostol (generic for Arthrotec)	
<b>COX-II SELECTIVE</b>		
celecoxib (generic for Celebrex)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## NSAIDs, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
diclofenac sodium <b>GEL (OTC only)</b>	diclofenac (generic for Pennsaid Solution) <sup>CL</sup> FLECTOR <b>PATCH</b> (diclofenac) <sup>CL</sup> LICART <b>PATCH</b> (diclofenac) <sup>CL</sup> PENNSAID <b>PACKET, PUMP</b> (diclofenac) <sup>CL</sup> VOLTAREN <b>GEL</b> (diclofenac) <sup>CL</sup>	<p>Non-preferred agents will be approved for patients who have failed ONE preferred agent within this drug class</p> <p>Drug Specific Criteria</p> <ul style="list-style-type: none"> <li><b>Flector®/Licart:</b> Approved for diagnosis of acute pain due to sprain/strain/contusion AND trial of oral diclofenac OR clinical reason patient cannot use oral dosage form</li> <li><b>Pennsaid®:</b> Approved for osteoarthritis of the knees AND trial of oral diclofenac OR clinical reason patient cannot use oral dosage form</li> <li><b>Pennsaid® Pump:</b> Requires clinical reason why 1.5% solution cannot be used</li> <li><b>Voltaren®:</b> Approved for diagnosis of osteoarthritis AND trial of oral diclofenac OR clinical reason patient cannot use oral dosage form</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

**NOTE: Other oral oncology agents not listed here may also be available. See <https://nebraska.fhsc.com/default.asp> for coverage information and prior authorization status for products not listed.**

## ONCOLOGY AGENTS, ORAL, BREAST

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CDK 4/6 INHIBITOR</b>		<ul style="list-style-type: none"> <li>• Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> </ul> <ul style="list-style-type: none"> <li>Drug-specific criteria               <ul style="list-style-type: none"> <li>▪ <b>anastrozole:</b> May be approved for malignant neoplasm of male breast (male breast cancer)</li> <li>▪ <b>capecitabine:</b> Requires trial of Xeloda or clinical reason Xeloda cannot be used</li> <li>▪ <b>Fareston®:</b> Require clinical reason why tamoxifen cannot be used</li> <li>▪ <b>letrozole:</b> Approved for diagnosis of breast cancer with day supply greater than 12 – NOT approved for short term use</li> <li>▪ <b>Soltamox:</b> May be approved with documented swallowing difficulty</li> </ul> </li> </ul>
IBRANCE (palbociclib)	KISQALI (ribociclib) KISQALI FEMARA <b>CO-PACK</b> VERZENIO (abemaciclib)	
<b>CHEMOTHERAPY</b>		
cyclophosphamide XELODA (capecitabine)	capecitabine (generic for Xeloda) <sup>CL</sup>	
<b>HORMONE BLOCKADE</b>		
anastrozole (generic for Arimidex) exemestane (generic for Aromasin) letrozole (generic for Femara) tamoxifen citrate (generic for Nolvadex)	SOLTAMOX <b>SOLN</b> (tamoxifen) <sup>CL</sup> toremifene (generic for Fareston) <sup>CL</sup>	
<b>OTHER</b>		
	NERLYNX (neratinib) PIQRAY (alpelisib) <b>lapatinib (generic Tykerb)</b> <sup>CL</sup> TALZENNA (talazoparib tosylate) <sup>QL</sup> TUKYSA(tucatinib) <sup>QL</sup>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

**NOTE: Other oral oncology agents not listed here may also be available. See <https://nebraska.fhsc.com/default.asp> for coverage information and prior authorization status for products not listed.**

## ONCOLOGY AGENTS, ORAL, HEMATOLOGIC

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ALL</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> <li>Drug-specific criteria               <ul style="list-style-type: none"> <li>▪ <b>Hydrea®:</b> Requires clinical reason why generic cannot be used</li> <li>▪ <b>Melphalan:</b> Requires trial of Alkeran or clinical reason Alkeran cannot be used</li> <li>▪ <b>Purixan:</b> Prior authorization not required for age ≤12 or for documented swallowing disorder</li> <li>▪ <b>Tabloid:</b> Prior authorization not required for age &lt;19</li> <li>▪ <b>Tasigna:</b> Patients receiving Tasigna, which changed from preferred to non-preferred on 1-17-19 will be allowed to continue therapy</li> <li>▪ <b>Xpovio:</b> Indicated for relapsed or refractory multiple myeloma. Requires concomitant therapy with dexamethasone</li> </ul> </li> </ul>
mercaptopurine	PURIXAN (mercaptopurine) <sup>AL</sup>	
<b>AML</b>		
	DAURISMO (glasdegib maleate) <sup>QL</sup> IDHIFA (enasidenib) RYDAPT (midostaurin) TIBSOVO (ivosidenib) <sup>QL</sup> XOSPATA (gilteritinib) <sup>QL</sup>	
<b>CLL</b>		
IMBRUVICA (ibrutinib) LEUKERAN (chlorambucil) VENCLEXTA (venetoclax)	COPIKTRA (duvelisib) <sup>QL</sup> ZYDELIG (idelalisib)	
<b>CML</b>		
hydroxyurea (generic for Hydrea) imatinib (generic for Gleevec) MYLERAN (busulfan) SPRYCEL (dasatinib)	BOSULIF (bosutinib) GLEEVEC (imatinib) HYDREA (hydroxyurea) ICLUSIG (ponatinib) SCEMBLIX (asciminib) <sup>NR</sup> TASIGNA (nilotinib) <sup>CL</sup>	
<b>MPN</b>		
JAKAFI (ruxolitinib)		
<b>MYELOMA</b>		
ALKERAN (melphalan) REVLIMID (lenalidomide)	FARYDAK (panobinostat) melphalan (generic for Alkeran) NINLARO (ixazomib) POMALYST (pomalidomide) THALOMID (thalidomide) XPOVIO (selinexor) <sup>CL</sup>	
<b>OTHER</b>		
MATULANE (procarbazine) TABLOID (thioguanine) tretinoin (generic for Vesanoïd)	BRUKINSA (zanubrutinib) <sup>QL</sup> CALQUENCE (acalabrutinib) <sup>QL</sup> INREBIC (fedratinib dihydrochloride) <sup>QL</sup> INQOVI (decitabine/cedazuridine) <b>UKONIQ (umbralisib)<sup>NR</sup></b> ZOLINZA (vorinostat)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

**NOTE: Other oral oncology agents not listed here may also be available. See <https://nebraska.fhsc.com/default.asp> for coverage information and prior authorization status for products not listed.**

## ONCOLOGY AGENTS, ORAL, LUNG

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria	
<b>ALK</b>			
ALECENSA (alectinib)	ALUNBRIG (brigatinib) LORBRENA (lorlatinib) <sup>QL</sup> ZYKADIA (ceritinib) <b>CAPSULE, TABLET</b>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> <li>Drug-Specific Criteria</li> <li>▪ <b>Iressa/ Xalkori:</b> Patients receiving Iressa or Xalkori prior to 1/21/21 (which changed from preferred to non-preferred) will be allowed to continue current treatment</li> </ul>	
<b>ALK / ROS1 / NTRK</b>			
	ROZLYTREK (entrectinib) <sup>AL,QL</sup> XALKORI (crizotinib)		
<b>EGFR</b>			
TAGRISSO (osimertinib)	erlotinib (generic for Tarceva) EXKIVITY (mobocertinib) <sup>NR,QL</sup> GILOTRIF (afatinib) IRESSA (gefitinib) TARCEVA (erlotinib) VIZIMPRO (dacomitinib) <sup>QL</sup>		
<b>OTHER</b>			
	GAVRETO ( <i>pralsetinib</i> ) <sup>QL</sup> HYCANTIN (topotecan) <b>LUMAKRAS (<i>sotrasib</i>)<sup>QL</sup></b> <b>RETEVMO (<i>selpercatinib</i>)<sup>AL</sup></b> <b>TABRECTA (<i>capmatinib</i>)<sup>QL</sup></b> <b>TEPMETKO (<i>tepotinib</i>)<sup>QL</sup></b>		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

**NOTE: Other oral oncology agents not listed here may also be available. See <https://nebraska.fhsc.com/default.asp> for coverage information and prior authorization status for products not listed.**

## ONCOLOGY AGENTS, ORAL, OTHER

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
CAPRELSA (vandetanib) GLEOSTINE (lomustine) LYNPARZA (olaparib) temozolomide (generic for Temodar) ZEJULA (niraparib)	AYVAKIT (avapritinib) <sup>AL,NR,QL</sup> BALVERSA (erdafitinib) COMETRIQ (cabozantinib) HEXALEN (altretamine) KOSELUGO (selumetinib) <sup>AL</sup> LONSURF (trifluridine/tipiracil) PEMAZYRE (pemigatinib) <sup>QL</sup> RUBRACA (rucaparib) STIVARGA (regorafenib) TAZVERIK (tazemetostat) <sup>AL</sup> TURALIO (pexidartinib) <sup>QL</sup> <b>TRUSELTIQ (infigratinib) CAPSULE</b> VITRAKVI (larotrectinib) <b>CAPSULE, SOLUTION</b> <sup>QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

**NOTE: Other oral oncology agents not listed here may also be available. See <https://nebraska.fhsc.com/default.asp> for coverage information and prior authorization status for products not listed.**

## ONCOLOGY AGENTS, ORAL, PROSTATE

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
abiraterone (generic for Zytiga) <sup>AL,QL</sup> bicalutamide (generic for Casodex) flutamide XTANDI (enzalutamide) <sup>AL,QL</sup> ZYTIGA (abiraterone) <sup>AL,QL</sup>	EMCYT (estramustine) ERLEADA (apalutamide) <sup>QL</sup> nilutamide (generic for Nilandron) NUBEQA (darolutamide) <sup>QL</sup> YONSA (abiraterone acetone, submicronized)	<ul style="list-style-type: none"> <li>Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> </ul>

## ONCOLOGY AGENTS, ORAL, RENAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
INLYTA (axitinib) LENVIMA (lenvatinib) SUTENT (sunitinib) VOTRIENT (pazopanib)	AFINITOR DISPERZ (everolimus) <sup>CL</sup> CABOMETYX (cabozantinib) everolimus (generic for Afinitor) everolimus <b>SUSP</b> (generic for Afinitor Disperz) <sup>NR</sup> FOTIVDA (tivozanib) <sup>NR</sup> NEXAVAR (sorafenib) sunitinib malate (generic for Sutent) WELIREG (belzutifan) <sup>NR,QL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> </ul> <p>Drug-specific criteria</p> <ul style="list-style-type: none"> <li><b>Afinitor:</b> Patients receiving Afinitor, which changed from preferred to non-preferred on 1-17-19 will be allowed to continue therapy</li> </ul>

## ONCOLOGY AGENTS, ORAL, SKIN

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BASAL CELL</b>		<ul style="list-style-type: none"> <li>Non-preferred agents DO NOT require a trial of a preferred agent, but DO require an FDA-approved indication OR documentation submitted supporting off-label use from current treatment guidelines</li> </ul>
ERIVEDGE (vismodegib)	ODOMZO (sonidegib) <sup>CL</sup>	
<b>BRAF MUTATION</b>		<p>Drug-specific criteria</p> <ul style="list-style-type: none"> <li><b>Odomzo:</b> Patients receiving Odomzo, which changed from preferred to non-preferred on 1-17-19 will be allowed to continue therapy</li> </ul>
MEKINIST (trametinib) TAFINLAR (dabrafenib)	BRAFTOVI (encorafenib) COTELLIC (cobimetinib) MEKTOVI (binimetinib) ZELBORAF (vemurafenib)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## OPHTHALMICS, ALLERGIC CONJUNCTIVITIS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ALREX (loteprednol 0.2%) cromolyn (generic for Opticrom) ketotifen OTC (generic for Zaditor) olopatadine 0.1% (generic for Patanol) olopatadine 0.2% (generic for Pataday once daily, Pataday twice daily)	ALOCRIL (nedocromil) ALOMIDE (Iodoxamide) azelastine (generic for Optivar) BEPREVE (bepotastine besilate) bepotastine besilate (generic for Bepreve) EMADINE (emedastine) epinastine (generic for Elestat) LASTACAFT (alcaftadine) PATADAY XS (olopatadine 0.7%) PATADAY OTC (olopatadine 0.2%) PAZEO (olopatadine 0.7%) ZERVIAE (certirizine) <sup>AL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## OPHTHALMICS, ANTIBIOTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>FLUOROQUINOLONES</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a one-month trial of TWO preferred agent within this drug class</li> <li>▪ <b>Azasite®</b>: Approval only requires trial of erythromycin</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>Natacyn®</b>: Approved for documented fungal infection</li> </ul>
ciprofloxacin <b>SOLUTION</b> (generic for Ciloxan) ofloxacin (generic for Ocuflax)	BESIVANCE (besifloxacin) CILOXAN (ciprofloxacin) gatifloxacin 0.5% (generic for Zymaxid) levofloxacin MOXEZA (moxifloxacin) moxifloxacin (generic for Vigamox) moxifloxacin (generic for Moxeza) VIGAMOX (moxifloxacin)	
<b>MACROLIDES</b>		
erythromycin	AZASITE (azithromycin) <sup>CL</sup>	
<b>AMINOGLYCOSIDES</b>		
gentamicin <b>OINTMENT</b> gentamicin <b>SOLUTION</b> tobramycin (generic for Tobrex drops)	TOBREX <b>OINTMENT</b> (tobramycin)	
<b>OTHER OPHTHALMIC AGENTS</b>		
bacitracin/polymyxin B (generic Polysporin) polymyxin B/trimethoprim (generic for Polytrim)	bacitracin NATACYN (natamycin) <sup>CL</sup> neomycin/bacitracin/polymyxin B <b>OINTMENT</b> neomycin/polymyxin B/gramicidin NEOSPORIN (neomycin/polymyxin B/gramicidin) sulfacetamide <b>SOLUTION</b> (generic for Bleph-10) sulfacetamide <b>OINTMENT</b>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## OPHTHALMICS, ANTIBIOTIC-STEROID COMBINATIONS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
neomycin/polymyxin/dexamethasone (generic for Maxitrol) sulfacetamide/prednisolone <b>TOBRADEX SUSPENSION, OINTMENT</b> (tobramycin and dexamethasone)	BLEPHAMIDE (prednisolone and sulfacetamide) BLEPHAMIDE S.O.P. neomycin/polymyxin/HC neomycin/bacitracin/poly/HC <b>PRED-G SUSPENSION, OINTMENT</b> (prednisolone/gentamicin) tobramycin/dexamethasone <b>SUSPENSION</b> (generic for Tobradex) <b>TOBRADEX S.T.</b> (tobramycin and dexamethasone) ZYLET (loteprednol, tobramycin)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## OPHTHALMICS, ANTI-INFLAMMATORIES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CORTICOSTEROIDS</b>		
fluorometholone 0.1% (generic for FML) <b>OINTMENT</b> LOTEMAX <b>SOLUTION</b> (loteprednol 0.5%) MAXIDEX (dexamethasone) PRED MILD (prednisolone 0.12%)	dexamethasone (generic for Maxidex) difluprednate (generic Durezol) <sup>NR</sup> DUREZOL (difluprednate) FLAREX (fluorometholone) FML (fluorometholone 0.1% <b>SOLUT.</b> ) FML FORTE (fluorometholone 0.25%) FML S.O.P. (fluorometholone 0.1%) INVELTYS (loteprednol etabonate) LOTEMAX <b>OINTMENT, GEL</b> (loteprednol) <i>loteprednol <b>GEL</b> (generic for Lotemax Gel)</i> loteprednol 0.5% SOLUTION (generic for Lotemax SOLUTION) prednisolone acetate 1% (gen. for Omnipred, Pred Forte) prednisolone sodium phosphate prednisolone sodium phosphate 1%	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> <li>▪ <b>NSAID class:</b> Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent</li> </ul>
<b>NSAID</b>		
diclofenac (generic for Voltaren) ketorolac 0.5% (generic for Acular)	ACUVAIL (ketorolac 0.45%) BROMSITE (bromfenac) bromfenac 0.09% (generic for Bromday) flurbiprofen (generic for Ocufer) ILEVRO (nepafenac 0.3%) ketorolac LS 0.4% (generic for Acular LS) NEVANAC (nepafenac) PROLENSA (bromfenac 0.07%)	

## OPHTHALMICS, ANTI-INFLAMMATORY / IMMUNOMODULATORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
RESTASIS (cyclosporine) RESTASIS MULTIDOSE (cyclosporine) XIIDRA (lifitegrast)	<i>CEQUA (cyclosporine)<sup>QL</sup></i> <i>EYSUVIS (loteprednol etabonate)<sup>QL</sup></i> <i>TYRVAYA (varenicline tartrate)<sup>NR, QL</sup></i>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## OPHTHALMICS, GLAUCOMA

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>MIOTICS</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>
pilocarpine	PHOSPHOLINE IODIDE (echothiophate iodide) VUITY (pilocarpine) <sup>NR</sup>	
<b>SYMPATHOMIMETICS</b>		
Alphagan P (brimonidine 0.15%) brimonidine 0.2% (generic for Alphagan)	Alphagan P (brimonidine 0.1%) apraclonidine (generic for lopidine) brimonidine P 0.15%	
<b>BETA BLOCKERS</b>		
levobunolol (generic for Betagan) timolol (generic for Timoptic)	betaxolol (generic for Betoptic) BETIMOL (timolol) BETOPTIC S (betaxolol) carteolol (generic for Ocupress) timolol (generic for Istalol) <i>timolol (generic for Timoptic Ocudose)</i> TIMOPTIC OCUDOSE TIMOPTIC XE (timolol gel forming solution)	
<b>CARBONIC ANHYDRASE INHIBITORS</b>		
dorzolamide (generic for Trusopt)	AZOPT (brinzolamide) <i>brinzolamide (generic for Azopt)</i>	
<b>PROSTAGLANDIN ANALOGS</b>		
latanoprost (generic for Xalatan) TRAVATAN Z (travoprost)	bimatoprost (generic for Lumigan) travoprost (generic for Travatan Z) VYZULTA (latanoprostene) XALATAN (latanoprost) ZIOPTAN (tafluprost)	
<b>COMBINATION DRUGS</b>		
COMBIGAN (brimonidine/timolol) dorzolamide/timolol (generic for Cosopt)	dorzolamide/timolol PF (generic for Cosopt PF) SIMBRINZA (brinzolamide/brimonidine)	
<b>OTHER</b>		
RHOPRESSA (netarsudil) <sup>CL</sup> ROCKLATAN (netarsudil and latanoprost) <sup>CL</sup>		<p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>Rhopressa and Rocklatan:</b> Electronically approved for patients who have a trial of ONE generic agent, within ophthalmics-glaucoma within 60 days</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

<sup>NR</sup> – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## OPIOID DEPENDENCE TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
buprenorphine <b>SL</b> buprenorphine/naloxone <b>TAB (SL)</b> SUBOXONE <b>FILM</b> (buprenorphine/ naloxone)	BUNAVAIL (buprenorphine/naloxone) buprenorphine/naloxone <b>FILM</b> LUCEMYRA (lofexidine) <sup>CL,QL</sup> ZUBSOLV (buprenorphine/naloxone)	<p style="text-align: center;"><a href="#">Buprenorphine PA Form</a> <a href="#">Buprenorphine Informed Consent</a></p> Non-Preferred buprenorphine and buprenorphine /naloxone agents: <ul style="list-style-type: none"> <li>Diagnosis of Opioid Use Disorder, NOT approved for pain management</li> <li>Verification of “X” DEA license number of prescriber</li> <li>No concomitant opioids</li> <li>Failed trial of preferred drug or patient-specific documentation of why preferred product not appropriate for patient</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li><b>Lucemyra</b>: Approved for FDA approved indication and dosing per label. Trial of preferred product not required.</li> </ul>

## OPIOID-REVERSAL TREATMENTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
naloxone <b>SYRINGE, VIAL</b> naltrexone <b>TABLET</b> NARCAN (naloxone) <b>SPRAY</b>	KLOXXADO (naloxone) <sup>NR</sup> <b>NASAL</b> naloxone <b>SPRAY</b> (generic for Narcan) <sup>NR</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved with documentation of why preferred products within this drug class are not appropriate for the patient</li> </ul>

## OTIC ANTI-INFECTIVES & ANESTHETICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
acetic acid (generic for Vosol)	acetic acid/hydrocortisone (generic for Vosol HC)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of the preferred agent within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## OTIC ANTIBIOTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
CIPRODEX (ciprofloxacin/dexamethasone) neomycin/polymyxin/hydrocortisone (generic for Cortisporin) ofloxacin (generic for Floxin)	CIPRO HC (ciprofloxacin/ hydrocortisone) ciprofloxacin ciprofloxacin/dexamethasone (generic for CIPRODEX) COLY-MYCIN S(neomycin/ hydrocortisone/colistin) OTOVEL (ciprofloxacin/fluocinolone)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>

## PAH (PULMONARY ARTERIAL HYPERTENSION AGENTS), ORAL AND INHALED

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ambrisentan (generic Letairis) sildenafil <b>TABLET</b> (generic Revatio) <sup>CL</sup> tadalafil (generic for Adcirca) <sup>CL</sup> TRACLEER <b>TABLET</b> (bosentan) TYVASO <b>INHALATION</b> (treprostinil) VENTAVIS <b>INHALATION</b> (iloprost)	ADEMPAS (riociguat) <sup>CL</sup> ADCIRCA (tadalafil) <sup>CL</sup> bosentan <b>TABLET</b> (generic Tracleer) LETAIRIS (ambrisentan) OPSUMIT (macitentan) ORENITRAM ER (treprostinil) sildenafil <b>SUSPENSION</b> (generic Revatio) <sup>CL</sup> TRACLEER <b>TABLETS FOR SUSPENSION</b> (bosentan) UPTRAVI (selexipag)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class within the last 6 months</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>Adcirca®/Revatio®</b>: Approved for diagnosis of Pulmonary Arterial Hypertension (PAH)</li> <li>▪ <b>Adempas®</b>:                      PAH: Requires clinical reason preferred agent cannot be used                      CTEPH: Approved for persistent/recurrent diagnosis after surgical treatment or inoperable CTEPH                      NOT for use in Pregnancy</li> <li>▪ <b>sildenafil suspension</b>: Requires clinical reason why sildenafil tablets cannot be used</li> </ul>

## PANCREATIC ENZYMES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
CREON ZENPEP (pancrelipase)	PANCREAZE (pancrelipase) PERTZYE (pancrelipase) VIOKACE (pancrelipase)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## PEDIATRIC VITAMIN PREPARATIONS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<p>CHILD LITTLE ANIMALS VITAMINS CHEW OTC (pedi multivit 91/iron fum) <b>CHEW</b></p> <p>child multivitamins chew otc (pedi multivit 19/folic acid) <b>CHEW</b></p> <p>CHILDREN'S CHEW MULTIVIT-IRON OTC (pedi multivit 91/iron fum) <b>CHEW</b></p> <p>children's chewables otc (pedi multivit 23/folic acid) <b>CHEW</b></p> <p>children's vitamins with iron otc (pedi multivit/iron)</p> <p>fluoride/vitamins A,C,AND D (pedi multivit A,C,D3, 21/fluoride) <b>DROPS</b></p> <p>infant-toddler multivit drop OTC (pediatric multivit no. 165 drops)</p> <p>infant-toddler multivit-iron OTC (pedi mv no.164/ferrous sulfate drops)</p> <p>infant-toddler tri-vit drop (vit a palmitate/vit c/vit d3 drops)</p> <p>multivitamins with fluoride (pedi multivit 2/fluoride) <b>DROPS</b></p> <p>multivits with iron and fluoride (pedi multivit 45/fluoride/iron) <b>DROPS</b></p> <p>MVC-FLUORIDE (pedi multivit 12/fluoride) <b>CHEW TAB</b></p> <p>ped mvi A,C,D3,No 21/fluoride <b>DROPS</b></p> <p>pedi mvi no. 16 with fluoride <b>CHEW</b></p> <p>pedi mvi 17 with fluoride <b>CHEW</b></p> <p>POLY-VI-SOL OTC (pedi multivit 81) <b>DROPS</b></p> <p>POLY-VI-SOL WITH IRON (pedi multivit 80/ferrous sulfate) <b>DROPS</b></p> <p>TRI-VI-SOL OTC (vit A palmitate/vit C/Vit D3) <b>DROPS</b></p> <p>tri-vite-fluoride 0.25 mg/ml, and 0.5 mg/ml</p> <p>VITALETS OTC (pedi multivit 36/iron) <b>CHEW</b></p>	<p>DEKAs PLUS (ped multivitamin no.128/vitamin K)<sup>NR</sup></p> <p>ESCAVITE (pedi multivit 47/iron/fluoride)</p> <p>ESCAVITE D (pedi multivit 78/iron/fluoride) <b>CHEW</b></p> <p>ESCAVITE LQ (pedi multivit 86/iron/fluoride)</p> <p>FLORIVA (pedi multivit 85/fluoride) <b>CHEW</b></p> <p>FLORIVA PLUS OTC and Rx (pedi multivit 130/fluoride) <b>DROPS</b></p> <p>multivit A, B, D, E, K, ZN (pediatric multivit 153/D3/K)</p> <p>POLY-VI-FLOR (pedi multivit 33/fluoride) <b>CHEW</b></p> <p>POLY-VI-FLOR (pedi multivit 37/fluoride) <b>DROPS</b></p> <p>POLY-VI-FLOR w/IRON (pedi multivit 33/fluoride/iron) <b>CHEW</b></p> <p>POLY-VI-FLOR w/IRON (pedi multivit 37/fluoride/iron) <b>DROPS</b></p> <p>QUFLORA OTC and Rx (pedi multivit 84/fluoride)</p> <p>QUFLORA FE (pedi multivit 142/iron/fluoride)</p> <p>TRI-VI-FLORO (ped multivit A, C, D3, 38/fluoride)</p>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul> <p>Drug specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>DEKAs Plus:</b> Approved for diagnosis of Cystic Fibrosis</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## PENICILLINS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
amoxicillin <b>CAPSULE, CHEWABLE TABLET, SUSP, TABLET</b> ampicillin <b>CAPSULE</b> dicloxacillin penicillin VK		<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a 3-day trial of ONE preferred agent within this drug class</li> </ul>

## PHOSPHATE BINDERS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
calcium acetate <b>TABLET, CAPSULE</b> CALPHRON OTC (calcium acetate) RENVELA (sevelamer carbonate)	AURYXIA (ferric citrate) ELIPHOS (calcium acetate) lanthanum (generic FOSRENOL) PHOSLO (calcium acetate) PHOSLYRA (calcium acetate) RENAGEL (sevelamer HCl) sevelamer HCl (generic Renagel) sevelamer carbonate (generic Renvela) VELPHORO (sucroferric oxyhydroxide)	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class within the last 6 months</li> </ul>

## PLATELET AGGREGATION INHIBITORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
AGGRENEX (dipyridamole/aspirin) aspirin BRILINTA (ticagrelor) clopidogrel (generic Plavix) dipyridamole (generic Persantine) prasugrel (generic Effient)	aspirin/dipyridamole (generic Aggrenox) ticlopidine (generic Ticlid) YOSPRALA (aspirin/omeprazole) ZONTIVITY (vorapaxar) <sup>CL</sup>	<ul style="list-style-type: none"> <li>Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class OR documented clopidogrel resistance</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li><b>Zontivity®</b>: Approved for reduction of thrombotic cardiovascular events in history of MI or with peripheral artery disease (PAD) Use with aspirin and/or clopidogrel</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## PRENATAL VITAMINS

Additional covered agents can be looked up using the Drug Look-up Tool at:

<https://druglookup.fhsc.com/druglookupweb/?client=nestate>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
c-nate dha <b>SOFTGEL</b> complete natal dha (pnv2/iron b-g suc-p/fa/omega-3) classic prenatal <b>TABLET</b> (prenatal vit/fe fum/fa) COMPLETENATE <b>CHEWABLE</b> pnv with ca, #72/iron/fa prenatal vitamin <b>TABLET</b> (pnv#124/iron/fa) prenatal no.137/iron/fa <b>OTC</b> pretab 29mg-1 <b>TABLET</b> (pnv#78/iron/fa) PUREFE PLUS PUREFE OB PLUS TRINATAL RX 1 virt-nate dha <b>SOFTGEL</b> (pnv 11-iron fum-fa-om3) zatean-pn plus <b>SOFTGEL</b> (pnv/ca no.68/iron/fa1/dha)	DERMACINRX PRENATRIX <b>CAPLET</b> (prenatal vit no. 170/fe/fa) DERMACINRX PRENATRYL <b>CAPLET</b> (prenatal vit no.170/fe/fa) DERMACINRX PRETRATE <b>CAPLET</b> (prenatal vit no. 170/fe/fa) <sup>NR</sup> folivane-ob <b>CAPSULE</b> (pnv#15/iron fum & ps cmp/fa) niva-plus <b>TABLET</b> (pnv with ca,no.74/iron/fa) <b>NEONATAL FE (iron/carb/vit C/vit                      B12/folic acid)</b> <sup>NR</sup> <b>NEONATAL PLUS(PNV No.154/iron                      fum/folic acid)</b> <sup>NR</sup> <b>NEONATAL-DHA (pnv                      No.175/iron/fa/dha/algae)</b> <sup>NR</sup> pnv-dha <b>SOFTGEL</b> (pnv combo#47/iron/fa #1/dha) taron-c dha <b>CAPSULE</b> (pnv#16/iron fum &ps/fa/om-3) virt-c dha <b>SOFTGEL</b> (pnv#16/iron fum &ps/fa/om-3) virt-pm dha <b>SOFTGEL</b> (pnv combo#47/iron/fa #1/dha) WESTGEL DHA (prenatal 93/iron/folate 9/dha) zatean-pn dha <b>CAPSULE</b> (pnv #47/iron/fa #1/dha)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of or are intolerant to TWO preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## PROGESTERONE (hydroxyprogesterone caproate)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
MAKENA <b>AUTO INJECTOR</b> (hydroxyprogesterone caproate)	hydroxyprogesterone caproate (generic Makena) MAKENA (hydroxyprogesterone caproate) <b>SDV</b>	<ul style="list-style-type: none"> <li>▪ When filled as outpatient prescription, use limited to:               <ul style="list-style-type: none"> <li>▪ Singleton pregnancy AND</li> <li>▪ Previous Pre-term delivery AND</li> <li>▪ No more than 20 doses (administered between 16 -36 weeks gestation)</li> <li>▪ Maximum of 30 days per dispensing</li> </ul> </li> </ul>

## PROTON PUMP INHIBITORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
omeprazole (generic Prilosec) <b>RX</b> pantoprazole (generic Protonix) <sup>QL</sup> PROTONIX <b>SUSP</b> (pantoprazole)	DEXILANT (dexlansoprazole) esomeprazole magnesium (generic Nexium) <b>RX, OTC</b> <sup>NR, QL</sup> esomeprazole strontium lansoprazole (generic Prevacid) <sup>QL</sup> NEXIUM <b>SUSPENSION</b> (esomeprazole) omeprazole/sodium bicarbonate (generic Zegerid <b>RX</b> ) <i>pantoprazole</i> <b>GRANULES</b> <sup>QL</sup> rabeprazole (generic Aciphex)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed an 8-week trial of BOTH preferred agents within this drug class</li> </ul> <p><b>Pediatric Patients:</b> Patients <math>\leq 4</math> years of age – No PA required for Prevacid 30mg or omeprazole 20mg capsules (used to compound suspensions).</p> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>Prilosec<sup>®</sup>OTC/Omeprazole OTC:</b> EXCLUDED from coverage Acceptable as trial instead of Omeprazole 20mg</li> <li>▪ <b>Prevacid Solutab:</b> may be approved after trial of compounded suspension. Patients <math>\geq 5</math> years if age- Only approve non-preferred for GI diagnosis if:           <ul style="list-style-type: none"> <li>▪ Child can not swallow whole generic omeprazole capsules OR,</li> <li>▪ Documentation that contents of capsule may not be sprinkled in applesauce</li> </ul> </li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## SEDATIVE HYPNOTICS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>BENZODIAZEPINES</b>		
temazepam 15mg, 30mg (generic for Restoril)	estazolam (generic for ProSom) flurazepam (generic for Dalmane) temazepam (generic for Restoril) 7.5mg, 22.5mg triazolam (generic for Halcion)	<ul style="list-style-type: none"> <li>▪ <b>Lunesta®/ Rozerem®/zolpidem ER:</b> Requires a trial with generic zolpidem within the last 12 months AND Trial OR Clinical reason why zaleplon and preferred benzodiazepine cannot be used</li> <li>▪ <b>Edluar®:</b> Requires a trial with generic zolpidem within the last 12 months AND Trial OR Clinical reason why zaleplon and preferred benzodiazepine cannot be used and Requires documentation of swallowing disorder</li> <li>▪ <b>flurazepam/triazolam:</b> Requires trial of preferred benzodiazepine</li> <li>▪ <b>Hetlioz®:</b> Requires trial with generic zolpidem within last 12 months AND clinical reason why zaleplon AND preferred benzodiazepine cannot be used</li> <li>▪ <b>Silenor®:</b> Must meet ONE of the following:                             <ul style="list-style-type: none"> <li>○ Contraindication to preferred oral sedative hypnotics</li> <li>○ Medical necessity for doxepin dose &lt; 10mg</li> <li>○ Age greater than 65 years old or hepatic impairment (3mg dose will be approved if this criteria is met)</li> </ul> </li> <li>▪ <b>temazepam 7.5mg/22.5mg:</b> Requires clinical reason why 15mg/30mg cannot be used</li> <li>▪ <b>zolpidem/zolpidem ER:</b> Maximum daily dose for females: Zolpidem 5mg; Zolpidem ER® 6.25mg</li> <li>▪ <b>zolpidem SL:</b> Requires clinical reason why half of zolpidem tablet cannot be used</li> </ul>
<b>OTHERS</b>		
zaleplon (generic for Sonata) zolpidem (generic for Ambien)	BELSOMRA (suvorexant) <sup>AL,QL</sup> DAYVIGO (lemborexant) <sup>AL,QL</sup> doxepin (generic for Silenor) EDLUAR (zolpidem sublingual) eszopiclone (generic for Lunesta) HETLIOZ (tasimelteon) <sup>CL</sup> <b>HETLIOZ LQ (tasimelteon)</b> <b>SUSP<sup>AL,QL</sup></b> ramelteon (generic for Rozerem) zolpidem ER (generic for Ambien CR) zolpidem SL (generic for Intermezzo)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## SICKLE CELL ANEMIA TREATMENT<sup>AL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
DROXIA (hydroxyurea)	ENDARI (L-glutamine) <sup>CL</sup> OXBRYTA (voxelotor) <sup>CL</sup> SIKLOS (hydroxyurea)	<p>Drug-Specific Criteria</p> <ul style="list-style-type: none"> <li>▪ <b>Endari:</b> Patient must have documented two or more hospital admissions per year due to sickle cell crisis despite maximum hydroxyurea dosage.</li> <li>▪ <b>Oxbryta:</b> Not indicated for sickle cell crisis. Patient must have had at least one sickle cell-related vaso-occlusive event within the past 12 months; AND baseline hemoglobin is 5.5 g/dL ≤ 10.5 g/dL; AND patient is not receiving concomitant, prophylactic blood transfusion therapy</li> <li>▪ <b>Siklos:</b> Approved for use in patients ages 2 to 17 years old</li> </ul>

## SINUS NODE INHIBITORS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
	CORLANOR SOLUTION, TABLET (ivabradine)	<ul style="list-style-type: none"> <li>▪ Diagnosis of Chronic Heart Failure with left ventricular ejection fraction less than or equal to 35%, AND</li> <li>▪ Sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, AND</li> <li>▪ On maximally tolerated doses of beta-blockers OR have a contraindication to beta-blocker use</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## SKELETAL MUSCLE RELAXANTS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
baclofen (generic Lioresal) chlorzoxazone (generic Parafon Forte) cyclobenzaprine (generic Flexeril) <sup>QL</sup> methocarbamol (generic Robaxin) tizanidine <b>TABLET</b> (generic Zanaflex)	carisoprodol (generic Soma) <sup>CL,QL</sup> carisoprodol compound cyclobenzaprine ER (generic Amrix) <sup>CL</sup> dantrolene (generic Dantrium) FEXMID (cyclobenzaprine ER) LORZONE (chlorzoxazone) <sup>CL</sup> metaxalone (generic Skelaxin) NORGESIC FORTE (orphenadrine/ASA/caffeine) orphenadrine ER PARAFON FORTE (chlorzoxazone) tizanidine <b>CAPSULE</b> ZANAFLEX (tizanidine) <b>CAPSULE, TABLET</b>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a 1-week trial of TWO preferred agents within this drug class</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>cyclobenzaprine ER:</b> <ul style="list-style-type: none"> <li>○ Requires clinical reason why IR cannot be used</li> <li>○ Approved only for acute muscle spasms</li> <li>○ NOT approved for chronic use</li> </ul> </li> <li>▪ <b>carisoprodol:</b> <ul style="list-style-type: none"> <li>○ Approved for Acute, musculoskeletal pain - NOT for chronic pain</li> <li>○ Use is limited to no more than 30 days</li> <li>○ Additional authorizations will not be granted for at least 6 months following the last day of previous course of therapy</li> </ul> </li> <li>▪ <b>Dantrolene:</b> Trial NOT required for treatment of spasticity from spinal cord injury</li> <li>▪ <b>Lorzone<sup>®</sup>:</b> Requires clinical reason why chlorzoxazone cannot be used</li> <li>▪ <b>Soma<sup>®</sup> 250mg:</b> Requires clinical reason why 350mg generic strength cannot be used</li> <li>▪ <b>Zanaflex<sup>®</sup> Capsules:</b> Requires clinical reason generic cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## STEROIDS, TOPICAL

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>LOW POTENCY</b>		<ul style="list-style-type: none"> <li>▪ Low Potency Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>
hydrocortisone OTC & RX <b>CREAM, LOTION, OINTMENT (Rx only)</b> hydrocortisone/aloe <b>OINTMENT</b> SCALPICIN OTC (hydrocortisone)	ALA-CORT (hydrocortisone) <b>CREAM</b> ALA-SCALP HP (hydrocortisone) alclometasone dipropionate (generic for Aclovate) CAPEX <b>SHAMPOO</b> (fluocinolone) DESONATE (desonide) <b>GEL</b> desonide <b>LOTION</b> (generic for Desowen) desonide <b>CREAM, OINTMENT</b> (generic for former products Desowen, Tridesilon) fluocinolone 0.01% <b>OIL</b> (generic for DERMA-SMOOTHIE-FS) hydrocortisone/aloe <b>CREAM</b> hydrocortisone <b>OTC OINTMENT</b> MICORT-HC (hydrocortisone) TEXACORT (hydrocortisone)	
<b>MEDIUM POTENCY</b>		<ul style="list-style-type: none"> <li>▪ Medium Potency Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>
fluticasone propionate <b>CREAM, OINTMENT</b> (generic for Cutivate) mometasone furoate <b>CREAM, OINTMENT, SOLUTION</b> (generic for Elocon)	betamethasone valerate (generic for Luxiq) clocortolone (generic for Cloderm) fluocinolone acetonide (generic for Synalar) flurandrenolide (generic for Cordran) fluticasone propionate <b>LOTION</b> (generic for Cutivate) hydrocortisone butyrate (generic for Locoid) hydrocortisone butyrate/emoll (generic for Locoid Lipocream) hydrocortisone valerate (generic for Westcort) PANDEL (hydrocortisone probutate 0.1%) prednicarbate (generic for Dermatop)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## STEROIDS, TOPICAL (Continued)

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>HIGH POTENCY</b>		
triamcinolone acetonide <b>OINTMENT, CREAM</b> triamcinolone <b>LOTION</b>	amcinonide <b>CREAM, LOTION, OINTMENT</b> betamethasone dipropionate betamethasone / propylene glycol betamethasone valerate desoximetasone diflorasone diacetate fluocinonide <b>SOLUTION</b> fluocinonide <b>CREAM, GEL, OINTMENT</b> fluocinonide emollient halcinonide <b>CREAM</b> (generic for Halog) HALOG (halcinonide) <b>CREAM, OINT, SOLN</b> KENALOG AEROSOL (triamcinolone) SERNIVO (betamethasone dipropionate) triamcinolone <b>SPRAY</b> (generic for Kenalog spray) TRIANEX <b>OINTMENT</b> (triamcinolone) VANOS (fluocinonide)	<ul style="list-style-type: none"> <li>High Potency Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>
<b>VERY HIGH POTENCY</b>		
clobetasol emollient (generic for Temovate-E) clobetasol propionate <b>CREAM, GEL, OINTMENT, SOLUTION</b> halobetasol propionate (generic for Ultravate)	APEXICON-E (diflorasone) BRYHALI (halobetasol prop) <b>LOTION</b> clobetasol <b>SHAMPOO, LOTION</b> clobetasol propionate <b>FOAM, SPRAY</b> CLOBEX (clobetasol) halobetasol propionate <b>FOAM</b> (generic for Lexette) <sup>AL,QL</sup> <b>IMPEKLO (clobetasol) LOTION<sup>AL</sup></b> LEXETTE(halobetasol propionate) <sup>AL,QL</sup> OLUX-E /OLUX/OLUX-E CP (clobetasol)	<ul style="list-style-type: none"> <li>Very High Potency Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## STIMULANTS AND RELATED AGENTS<sup>AL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>CNS STIMULANTS</b>		<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul>
<b>Amphetamine type</b>		
ADDERALL XR (amphetamine salt combo) amphetamine salt combination IR VYVANSE (lisdexamfetamine) <sup>QL</sup> <b>CAPSULE, CHEWABLE</b>	ADZENYS XR (amphetamine) amphetamine ER (generic for Adzenys ER) <b>SUSPENSION</b> amphetamine salt combination ER (generic for Adderall XR) amphetamine sulfate (generic for Evekeo) <b>AZSTARYS (serdexmethylphenidate and dexamethylphenidate)<sup>QL</sup></b> dextroamphetamine (generic for Dexedrine) dextroamphetamine <b>SOLUTION</b> (generic for Procentra) dextroamphetamine ER (generic for Dexedrine ER) DYANAVEL XR (amphetamine) EVEKEO ODT (amphetamine sulfate) MYDAYIS (amphetamine salt combo) <sup>QL</sup> methamphetamine (generic for Desoxyn) ZENZEDI (dextroamphetamine)	Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Procentra®</b>: May be approved with documentation of swallowing disorder</li> <li>▪ <b>Zenedi®</b>: Requires clinical reason generic dextroamphetamine IR cannot be used</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## STIMULANTS AND RELATED ADHD DRUGS (Continued)<sup>AL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>Methylphenidate type</b>		
<p>CONCERTA (methylphenidate ER)<sup>QL</sup> 18mg, 27mg, 36mg, 54mg dexamethylphenidate (generic for Focalin IR) FOCALIN XR (dexamethylphenidate) <b>METHYLIN SOLUTION</b> (methylphenidate) methylphenidate (generic for Ritalin) methylphenidate <b>SOLUTION</b> (generic for Methylin) QUILLICHEW ER <b>CHEWTAB</b> (methylphenidate)</p>	<p>ADHANSIA XR (methylphenidate)<sup>QL</sup> APTENSIO XR (methylphenidate) COTEMPLA XR-ODT (methylphenidate)<sup>QL</sup> DAYTRANA <b>PATCH</b> (methylphenidate)<sup>QL</sup> dexamethylphenidate XR (generic for Focalin XR) FOCALIN IR (dexamethylphenidate) JORNAY PM (methylphenidate)<sup>QL</sup> <i>methylphenidate 50/50 (generic for Ritalin LA)</i> <i>methylphenidate 30/70 (generic for Metadate CD)</i> methylphenidate ER 18mg, 27mg, 36mg, 54mg (generic Concerta)<sup>QL</sup> methylphenidate ER <b>CAP</b> (generic for Aptensio XR)<sup>QL</sup> Methylphenidate ER (generic for Metadate ER) methylphenidate ER 72mg (generic for RELEXXII)<sup>QL</sup> methylphenidate ER (generic for Ritalin SR) <b>QUILLIVANT XR SUSP</b> (methylphenidate) RITALIN (methylphenidate)</p>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of TWO preferred agents within this drug class</li> <li>▪ Maximum accumulated dose of 108mg per day for ages &lt; 18</li> <li>▪ Maximum accumulated dose of 72mg per day for ages &gt; 19</li> </ul> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>Daytrana</b><sup>®</sup>: May be approved in history of substance use disorder by parent, caregiver, or patient. May be approved with documentation of difficulty swallowing</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## STIMULANTS AND RELATED ADHD DRUGS (Continued)<sup>AL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>MISCELLANEOUS</b>		<p><b>Note: generic guanfacine IR and clonidine IR are available without prior authorization</b></p> <p>Drug-specific criteria:</p> <ul style="list-style-type: none"> <li>▪ <b>armodafinil and Sunosi:</b> Require trial of modafinil</li> <li>▪ <b>armodafinil and modafinil:</b> approved only for: <ul style="list-style-type: none"> <li>○ Sleep Apnea with documentation/confirmation via sleep study and documentation that C-PAP has been maxed</li> <li>○ Narcolepsy with documentation of diagnosis via sleep study</li> <li>○ Shift Work Sleep Disorder (only approvable for 6 months) with work schedule verified and documented. Shift work is defined as working the all night shift</li> </ul> </li> <li>▪ <b>Sunosi</b> approved only for: <ul style="list-style-type: none"> <li>○ Sleep Apnea with documentation/confirmation via sleep study and documentation that C-PAP has been maxed</li> <li>○ Narcolepsy with documentation of diagnosis via sleep study</li> </ul> </li> <li>▪ <i>Wakix: approved only for excessive daytime sleepiness in adults with narcolepsy with documentation of narcolepsy diagnosis via sleep study</i></li> </ul>
atomoxetine (generic for Strattera) <sup>QL</sup> guanfacine ER (generic for Intuniv) <sup>QL</sup>	clonidine ER (generic for Kapvay) <sup>QL</sup> <b>QELBREE (viloxazine)<sup>QL</sup></b> STRATTERA (atomoxetine)	
<b>ANALEPTICS</b>		
	armodafinil (generic for Nuvigil) <sup>CL</sup> modafanil (generic for Provigil) <sup>CL</sup> SUNOSI (solriamfetol) <sup>CL,QL</sup> WAKIX (pitolisant) <sup>CL,QL</sup>	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## TETRACYCLINES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
doxycycline hyclate IR (generic Vibramycin) doxycycline monohydrate <b>50MG, 100MG CAPSULE</b> doxycycline monohydrate <b>SUSP, TABLET</b> (generic Vibramycin) minocycline HCl <b>CAPSULE, TABLET</b> (generic Dynacin/ Minocin/ Myrac)	demeclocycline (generic Declomycin) <sup>CL</sup> DORYX MPC DR (doxycycline pelletized) doxycycline hyclate DR (generic Doryx) doxycycline monohydrate 40MG, 75MG and 150MG <b>CAPSULES</b> (generic for Adoxa/Monodox/ Oracea) minocycline HCl ER (generic Solodyn) NUZYRA (omadacycline) tetracycline VIBRAMYCIN <b>SUSP</b> (doxycycline) XIMINO (minocycline ER) <sup>QL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a 3-day trial of TWO preferred agents within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Demeclocycline:</b> Approved for diagnosis of SIADH</li> <li>▪ <b>Doryx®/doxycycline hyclate DR/ Dynacin®/Oracea®/Solodyn®:</b> Requires clinical reason why generic doxycycline, minocycline or tetracycline cannot be used</li> <li>▪ <b>doxycycline suspension:</b> May be approved with documented swallowing difficulty</li> </ul>

## THROMBOPOIESIS STIMULATING PROTEINS<sup>CL</sup>

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<i>PROMACTA (eltrombopag) TABLET<sup>CL</sup></i>	<i>DOPTELET (avatrombopag)</i> <i>MULPLETA (lusutrombopag)</i> <i>PROMACTA (eltrombopag) SUSP</i> <i>TAVALLISSE (fostamatinib)</i>	<ul style="list-style-type: none"> <li>▪ All agents will be approved with FDA-approved indication, ICD-10 code is required.</li> <li>▪ Non-preferred agents require a trial of a preferred agent with the same indication or a contraindication.</li> </ul> Drug-Specific Criteria <ul style="list-style-type: none"> <li>▪ <b>Doptelet/Mulpleta:</b> Approved for one course of therapy for a scheduled procedure with a risk of bleeding for treatment of thrombocytopenia in adult patients with chronic liver disease</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

<sup>CL</sup> – Prior Authorization / Class Criteria apply

<sup>QL</sup> – Quantity/Duration Limit

<sup>AL</sup> – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## THYROID HORMONES

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
levothyroxine <b>TABLET</b> (generic Synthroid) liothyronine <b>TABLET</b> (generic Cytomel) thyroid, pork <b>TABLET</b> UNITHROID (levothyroxine)	EUTHYROX (levothyroxine) LEVO-T (levothyroxine) <i>levothyroxine <b>CAPSULE</b> (generic for Tirosint)</i> THYROLAR <b>TABLET</b> (liotrix) THYQUIDITY (levothyroxine) <b>SOLN</b> TIROSINT <b>CAPSULE</b> (levothyroxine) TIROSINT-SOL <b>LIQUID</b> (levothyroxine) <sup>CL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Tirosint-Sol</b>: May be approved with documented swallowing difficulty</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply



# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting  
Highlighted in **Red Font**

## ULCERATIVE COLITIS

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
<b>ORAL</b>		
APRISO (mesalamine) Sulfasalazine IR, DR (generic Azulfidine) LIALDA (mesalamine)	balsalazide (generic Colazal) budesonide DR (generic Uceris) DIPENTUM (olsalazine) GIAZO (balsalazide) mesalamine ER (generic Apriso) mesalamine (generic Asacol HD/Delzicol/Lialda) PENTASA (mesalamine)	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>Asacol HD®/Delzicol DR®/Pentasa®</b>: Requires clinical reason why preferred mesalamine products cannot be used</li> <li>▪ <b>Giazo®</b>: Requires clinical reason why generic balsalazide cannot be used</li> </ul> NOT covered in females
<b>RECTAL</b>		
CANASA (mesalamine) ROWASA (mesalamine)	mesalamine <b>ENEMA</b> (generic Rowasa) mesalamine <b>SUPPOSITORY</b> (generic Canasa) UCERIS (budesonide)	

## UTERINE DISORDER TREATMENT

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
ORIAHNN (elagolix/ estradiol/ norethindrone) <sup>AL,CL</sup> ORILISSA (elagolix sodium) <sup>QL,CL</sup>	MYFEMBREE (relugolix/ estradiol/ norethindrone acetate) <sup>AL, NR, QL</sup>	Drug-specific criteria: <ul style="list-style-type: none"> <li>• <b>Orilissa/Oriahnn</b>: Requires an FDA approved indication, must follow FDA dosing guidelines, and have had a trial and failure of an NSAID and oral contraceptive                             <ul style="list-style-type: none"> <li>○ Total duration of treatment is max of 24 months</li> </ul> </li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply

# Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria

Updates include November 2021 P&T Changes and new updates since the January 3rd posting

Highlighted in **Red Font**

## VASODILATORS, CORONARY

Preferred Agents	Non-Preferred Agents	Prior Authorization/Class Criteria
isosorbide dinitrate <b>TABLET</b> isosorbide dinitrate ER, SA <b>TABLET</b> (generic <b>Dilatrate-SR/Isordil</b> ) isosorbide mono IR/SR <b>TABLET</b> nitroglycerin <b>SUBLINGUAL,</b> <b>TRANSDERMAL</b> nitroglycerin ER <b>TABLET</b>	BIDIL (isosorbide dinitrate/ hydralazine) <sup>CL</sup> GONITRO (nitroglycerin) isosorbide dinitrate <b>TABLET</b> ( <b>Oceanside Pharm MFR only</b> ) NITRO-BID <b>OINTMENT</b> (nitroglycerin) NITRO-DUR (nitroglycerin) nitroglycerin <b>TRANSLINGUAL</b> (generic Nitrolingual) NITROMIST (nitroglycerin) VERQUVO ( <i>vericiguat</i> ) <sup>AL,CL,QL</sup>	<ul style="list-style-type: none"> <li>▪ Non-preferred agents will be approved for patients who have failed a trial of ONE preferred agent within this drug class</li> </ul> Drug-specific criteria: <ul style="list-style-type: none"> <li>▪ <b>BiDil:</b> Approved for the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients</li> <li>▪ <b>Verquvo:</b> Approved for use in patients following a recent hospitalization for HF within the past 6 months OR need for outpatient IV diuretics, in adults with symptomatic chronic HF and EF less than 45%</li> </ul>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL – Prior Authorization / Class Criteria apply

QL – Quantity/Duration Limit

AL – Age Limit

NR – Product was not reviewed - New Drug criteria will apply